



Edgar Filing: LANNETT CO INC - Form 10-Q/A

Yes

No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12B-12 of the Exchange Act).

Yes

No

As of September 21, 2007, there were 24,177,118 shares of the issuer's common stock, \$.001 par value, outstanding.

---

**EXPLANATORY NOTE**

This amendment on Form 10-Q/A (the Amendment ) amends and restates Lannett Company Inc. s quarterly report on Form 10-Q for the three months and nine months ended March 31, 2007, as initially filed with the Securities and Exchange Commission on May 7, 2007 (the Form 10-Q ).

The restatement is the result of an error identified in the fourth quarter of Fiscal 2007, which affected the first, second and third quarters of Fiscal 2007. We identified a number of production orders that were completed and removed from production in our information system during Fiscal 2007, but for which the month-end process to reduce the work in process (WIP) balance and expense the activity to cost of goods sold (COGS) in the general ledger did not occur. The result was that work in process inventory was overstated and cost of goods sold was understated by \$840,000 as of and for the year ended June 30, 2007, with the following quarterly pre tax accounting effect of the misstatement as follows: three months ended September 30, 2006 was \$394,000; three months ended December 31, 2006 was \$158,000; and three months ended March 31, 2007 was \$95,000. For further details, refer to Note 2 and Item 4.

Another error was identified in the fourth quarter of Fiscal 2007, resulting from the calculation of stock-based compensation expense. It also affected the first, second and third quarters of Fiscal 2007. We identified in the fourth quarter of Fiscal 2007 that the estimated life of stock options was calculated using the incorrect terms for valuing stock. The result was that stock compensation expense was misstated in each quarter of Fiscal 2007. The three quarters amounted to an overstatement of \$52,000 combined. For further details refer to Note 2 and Item 4.

An additional correction resulting from the impairment of the Cody Laboratories, Inc. ( Cody Labs ) note receivable was included in this Form 10-Q/A. Subsequent to filing Form 10-Q from March 31, 2007, the Company completed a third-party valuation of Cody Labs. The valuation concluded that the fair market value of Cody Labs as of March 31, 2007 was less than the note receivable amount outstanding as of March 31, 2007. As a result, this impairment of the note receivable is being recorded as of March 31, 2007. The restatement includes the loss on impairment of \$7,775,890 in the quarter ended March 31, 2007. For further details, refer to Note 2 and Item 4.

**Table of Contents**

**PART I. FINANCIAL INFORMATION**

**ITEM 1.**

**FINANCIAL STATEMENTS**

Consolidated Balance Sheets (unaudited) as of March 31, 2007 (restated) and June 30, 2006

Consolidated Statements of Operations (unaudited) for the three months and nine months ended March 31, 2007 (restated) and 2006

Consolidated Statement of Changes in Shareholders' Equity (unaudited) for the nine months ended March 31, 2007 (restated)

Consolidated Statements of Cash Flows (unaudited) for the nine months ended March 31, 2007 (restated) and 2006

Notes to Consolidated Financial Statements (unaudited) (restated)

**ITEM 2.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**ITEM 3.**

**QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**ITEM 4.**

**CONTROLS AND PROCEDURES**

**PART II. OTHER INFORMATION**

**ITEM 1.**

**LEGAL PROCEEDINGS**

**ITEM 6.**

**EXHIBITS AND REPORTS ON FORM 8-K**

**CERTIFICATION OF PRESIDENT & CHIEF EXECUTIVE OFFICER**

**CERTIFICATION OF VICE PRESIDENT OF FINANCE, TREASURER & CHIEF FINANCIAL OFFICER**

**CERTIFICATION PURSUANT TO SECTION 906 OF SARBANES OXLEY ACT OF 2002**

**PART I. FINANCIAL INFORMATION**

*ITEM 1. FINANCIAL STATEMENTS*

## LANNETT COMPANY, INC. AND SUBSIDIARIES

## CONSOLIDATED BALANCE SHEETS

	March 31, 2007 (unaudited) (restated, see Note 2)	June 30, 2006
<b>ASSETS</b>		
Current Assets		
Cash	\$ 4,316,849	\$ 468,359
Trade accounts receivable (net of allowance of \$250,000 for both periods)	29,057,307	24,921,671
Inventories	12,411,532	11,476,503
Interest receivable	81,309	193,549
Prepaid taxes	2,846,023	3,212,511
Deferred tax assets - current portion	1,461,172	1,461,172
Other current assets	1,853,514	1,753,082
<b>Total Current Assets</b>	<b>52,027,706</b>	<b>43,486,847</b>
Property, plant and equipment	31,854,565	28,782,350
Less accumulated depreciation	(11,007,325)	(9,136,801)
	20,847,240	19,645,549
Construction in progress	746,700	1,955,508
Investment securities - available for sale	3,780,094	5,621,609
Note receivable	2,733,846	3,182,498
Intangible asset (product rights) - net of accumulated amortization	12,492,668	13,831,168
Deferred tax asset	17,366,548	18,070,674
Other assets	231,832	198,211
<b>TOTAL ASSETS</b>	<b>\$ 110,226,634</b>	<b>\$ 105,992,064</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>LIABILITIES</b>		
Current Liabilities		
Accounts payable	\$ 9,403,063	\$ 763,744
Accrued expenses	5,737,048	5,217,894
Unearned grant funds	500,000	500,000
Current portion of long term debt	597,287	546,886
Rebates and chargebacks payables	11,847,254	13,012,084
<b>Total Current Liabilities</b>	<b>28,084,652</b>	<b>20,040,608</b>
Long term debt less current portion	7,193,145	7,649,806
Deferred tax liabilities	2,545,734	2,545,734
<b>TOTAL LIABILITIES</b>	<b>37,823,531</b>	<b>30,236,148</b>
<b>COMMITMENTS AND CONTINGENCIES</b>		
<b>SHAREHOLDERS' EQUITY</b>		
Common stock - authorized 50,000,000 shares, par value \$0.001; issued and outstanding, 24,165,325 and 24,141,325 shares, respectively	24,165	24,141
Additional paid in capital	72,708,625	71,742,402
Retained earnings	102,225	4,456,387
Accumulated other comprehensive loss	(37,342)	(72,444)
	72,797,673	76,150,486
Less: Treasury stock at cost - 50,900 shares	(394,570)	(394,570)
<b>TOTAL SHAREHOLDERS' EQUITY</b>	<b>72,403,103</b>	<b>75,755,916</b>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$ 110,226,634</b>	<b>\$ 105,992,064</b>

Edgar Filing: LANNETT CO INC - Form 10-Q/A

The accompanying notes to consolidated financial statements are an integral part of these statements.

**LANNETT COMPANY, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**



Edgar Filing: LANNETT CO INC - Form 10-Q/A

(UNAUDITED)

	Three months ended March 31, 2007 (restated, see Note 2)		Nine months ended March 31, 2007 (restated, see Note 2)	
	2006	2006	2006	2006
Net sales	\$ 20,302,576	\$ 15,737,180	\$ 65,186,747	\$ 44,607,481
Cost of sales (excluding amortization of intangible asset)	14,127,421	9,404,156	44,770,101	24,330,916
Gross profit	6,175,155	6,333,024	20,416,646	20,276,565
Research and development expenses	2,269,677	1,252,108	5,586,213	4,814,186
Selling, general & administrative expenses	3,132,486	2,554,595	9,485,724	7,332,135
Amortization of intangible assets	446,166	446,166	1,338,498	1,338,499
Loss on impairment	7,775,890		7,775,890	
Operating (loss) income	(7,449,064)	2,080,155	(3,769,679)	6,791,745
Other income (expense):				
Interest expense	(76,102)	(65,446)	(208,497)	(249,671)
Interest income	99,000	96,352	309,805	333,540
	22,898	30,906	101,308	83,869
Income (loss) before income tax (benefit) expense	(7,426,166)	2,111,061	(3,668,371)	6,875,614
Income tax (benefit) expense	(818,807)	856,402	685,791	2,752,335
Net (loss) income	\$ (6,607,359)	\$ 1,254,659	\$ (4,354,162)	\$ 4,123,279
Basic (loss) earnings per share	\$ (0.27)	\$ 0.05	\$ (0.18)	\$ 0.17
Diluted (loss) earnings per share	\$ (0.27)	\$ 0.05	\$ (0.18)	\$ 0.17
Basic weighted average number of shares	24,164,385	24,135,723	24,155,556	24,126,588
Diluted weighted average number of shares	24,164,385	24,201,162	24,155,556	24,174,198

The accompanying notes to consolidated financial statements are an integral part of these statements.

**LANNETT COMPANY, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS EQUITY**



Edgar Filing: LANNETT CO INC - Form 10-Q/A

(UNAUDITED)

	Common Stock Shares	Common Stock Amount	Additional Paid- in Capital	Retained Earnings (restated)	Treasury Stock (restated)	Accumulated Other Comprehensive Loss, net	Total Shareholders Equity (restated)
<b>Balance at June 30, 2006</b>	24,141,325	\$ 24,141	\$ 71,742,402	\$ 4,456,387	\$ (394,570)	\$ (72,444)	\$ 75,755,916
Shares issued in connection with employee stock purchase plan and exercise of stock options	24,000	24	109,355				109,379
Stock compensation expense (restated)			856,868				856,868
Other comprehensive income						35,102	35,102
Net (loss) income (restated)				(4,354,162)			(4,354,162)
<b>Balance at March 31, 2007</b> (restated, see Note 2)	24,165,325	\$ 24,165	\$ 72,708,625	\$ 102,225	\$ (394,570)	\$ (37,342)	\$ 72,403,103

The accompanying notes to consolidated financial statements are an integral part of this statement.

**LANNETT COMPANY, INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**



Edgar Filing: LANNETT CO INC - Form 10-Q/A

(UNAUDITED)

	For the nine months ended	
	2007	2006
	(restated, see Note 2)	
<b>OPERATING ACTIVITIES:</b>		
Net (loss) income	\$ (4,354,162)	\$ 4,123,279
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	3,293,232	2,918,531
Deferred tax expense	704,125	
Stock compensation expense	856,868	1,072,071
Gain from sale of asset	(8,208)	
Loss on impairment	7,775,890	
Changes in assets and liabilities which provided (used) cash:		
Trade accounts receivable	(5,188,226)	(8,980,283)
Inventories	(935,028)	(1,710,493)
Prepaid taxes	366,488	2,756,561
Prepaid expenses and other assets	(134,053)	(229,619)
Accounts payable	8,639,319	105,461
Accrued expenses	519,154	2,199,501
Net cash provided by operating activities	11,535,399	2,255,009
<b>INVESTING ACTIVITIES:</b>		
Purchases of property, plant and equipment (including construction in progress)	(1,949,407)	(4,033,852)
Proceeds from sale of asset	10,000	
Proceeds from sale of investment securities - available for sale	1,876,617	2,244,751
Issuance of note receivable	(7,327,238)	(2,000,000)
Net cash used in investing activities	(7,390,028)	(3,789,101)
<b>FINANCING ACTIVITIES:</b>		
Repayments of debt	(406,260)	(7,266,310)
Proceeds from grant funding		6,250,000
Proceeds from debt, net of restricted cash released		114,727
Proceeds from issuance of stock	109,379	(901,583)
Net cash used in financing activities	(296,881)	(901,583)
<b>NET INCREASE/(DECREASE) IN CASH</b>	<b>3,848,490</b>	<b>(2,435,675)</b>
<b>CASH, BEGINNING OF PERIOD</b>	<b>468,359</b>	<b>4,165,601</b>
<b>CASH, END OF PERIOD</b>	<b>\$ 4,316,849</b>	<b>\$ 1,729,926</b>
<b>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION -</b>		
Interest paid	\$ 121,833	\$ 231,853
Income taxes paid	\$ 650,000	\$

The accompanying notes to consolidated financial statements are an integral part of these statements.

**LANNETT COMPANY, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED**



**Note 1. Interim Financial Information**

The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles for presentation of interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited financial statements do not include all the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations, and cash flows for the periods presented. In the opinion of management, the unaudited financial statements include all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations, and cash flows for the periods presented. Operating results for the three month and nine month periods ended March 31, 2007 are not necessarily indicative of the results that may be expected for the year ending June 30, 2007. You should read these unaudited financial statements in combination with the other Notes in this section; Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2; and the Financial Statements, including the Notes to the Financial Statements, included in our Annual Report on Form 10-K for the year ended June 30, 2006.

**Note 2. Fiscal 2007 Restatement**

Lannett Company, Inc. is filing this amendment to its Quarterly Report on Form 10-Q for the period ended March 31, 2007, to amend and restate financial statements and other financial information for the three months and nine months ended March 31, 2007.

The restatement is the result of an error identified in the fourth quarter of Fiscal 2007, which affected the first, second and third quarters of Fiscal 2007. We identified a number of production orders that were completed and removed from production in our information system during Fiscal 2007, but for which the month-end process to reduce the work in process (WIP) balance and expense the activity to cost of goods sold (COGS) in the general ledger did not occur. The result was that WIP was overstated and COGS was understated by \$840,000 for the full year Fiscal 2007.

Another error was identified in the fourth quarter of Fiscal 2007, resulting from the calculation of stock-based compensation expense. It also affected the first, second and third quarters of Fiscal 2007. We identified in the fourth quarter of Fiscal 2007 that the estimated life of stock options was incorrectly calculated. The result was that stock compensation expense was misstated in each quarter of Fiscal 2007. The affect for the third quarter Fiscal 2007 was an overstatement of \$60,391. The three quarters amounted to an overstatement of \$52,000 combined.

An additional correction of an error resulting from the impairment of the Cody Laboratories, Inc. note receivable has been included in this Form 10-Q/A. Subsequent to filing Form 10-Q from March 31, 2007, the Company completed a third-party valuation of Cody Labs. The valuation concluded that the fair market value of Cody Labs as of March 31, 2007 was less than the note receivable amount outstanding as of March 31, 2007. As a result, this impairment of the note receivable is being recorded as of March 31, 2007. The restatement includes the loss on impairment of \$7,775,890 in the quarter ended March 31, 2007. See Note 18 Subsequent Event for more information relating to the acquisition. The impairment of \$7,775,890 is the difference between the amount outstanding from Cody Labs as of March 31, 2007 and the net assets of Cody Labs as of April 10, 2007.

This current Form 10-Q/A includes the effect of the adjustment from the three months and nine months ended March 31, 2007. The following table summarizes the effects of the change on relevant accounts within the Consolidated Balance Sheets and Consolidated Statements of Income:

Edgar Filing: LANNETT CO INC - Form 10-Q/A

	March 31, 2007	
	As previously reported	As restated
<b>Consolidated Balance Sheets</b>		
Inventories	\$ 13,058,531	\$ 12,411,531
Note receivable	\$ 10,509,736	\$ 2,733,846
Additional paid in capital	\$ 72,760,233	\$ 72,708,625
Deferred Tax Asset - Long Term	\$ 16,169,695	\$ 17,366,548

	Three months ended March 31, 2007	
	As previously reported	As restated
<b>Consolidated Statements of Operations</b>		
Cost of sales (excluding amortization of intangible asset)	\$ 14,032,421	\$ 14,127,421
Selling, general and administrative expense	\$ 3,192,877	\$ 3,132,486
Loss on impairment	\$	\$ 7,775,890
Operating income (loss)	\$ 361,435	\$ (7,449,064)
Income tax expense (benefit)	\$ 153,733	\$ (818,807)
Net income (loss)	\$ 230,600	\$ (6,607,359)
per share amounts		
Basic earnings (loss) per common share	\$ 0.01	\$ (0.27)
Diluted earnings (loss) per common share	\$ 0.01	\$ (0.27)
Basic shares outstanding	24,164,385	24,164,385
Diluted shares outstanding	24,218,406	24,164,385

This current Form 10-Q/A also includes the effect of the year-to-date adjustment, the impact of which is summarized as follows:

	Nine months ended March 31, 2007	
	As previously reported	As restated
<b>Consolidated Statements of Operations</b>		
Cost of sales (excluding amortization of intangible asset)	\$ 44,123,101	\$ 44,770,101
Selling, general and administrative expense	\$ 9,537,333	\$ 9,485,724
Loss on impairment	\$	\$ 7,775,890
Operating income (loss)	\$ 4,601,602	\$ (3,769,679)
Income tax expense	\$ 1,882,644	\$ 685,791
Net income (loss)	\$ 2,820,266	\$ (4,354,162)
per share amounts		
Basic earnings (loss) per common share	\$ 0.12	\$ (0.18)
Diluted earnings (loss) per common share	\$ 0.12	\$ (0.18)
Basic shares outstanding	24,155,556	24,155,556
Diluted shares outstanding	24,205,347	24,155,556

**Note 3. Summary of Significant Accounting Policies**

Lannett Company, Inc., a Delaware Corporation, and subsidiaries (the Company), develop, manufacture, package, market, and distribute pharmaceutical products sold under generic chemical names. The Company primarily manufactures solid oral dosage forms, including tablets and capsules, and is pursuing partnerships and research contracts for the development and production of other dosage forms, including liquids and injectable products.

Revenue recognition and accounts receivable, adjustments for chargebacks, rebates and returns, allowance for doubtful accounts and realization of deferred income tax assets represent significant estimates made by management.

**Principles of Consolidation** - The consolidated financial statements include the accounts of the operating parent company, Lannett Company, Inc., and its wholly owned subsidiaries, Lannett Holdings, Inc. and an inactive subsidiary.

**Revenue Recognition** - The Company maintains pricing agreements with all customers. Revenue is recognized at the agreed price upon delivery to the customer, when title and risk of loss have transferred to the customer, collectibility is reasonably assured and provisions for estimates, including rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments are reasonably determinable. Accruals for these provisions are presented in the consolidated financial statements as rebates and chargebacks payable on the balance sheet and are included in net sales, as reductions, on the statement of income. Net sales, as presented in the statements of income, are based upon revenue earned upon shipment, less reserves for chargebacks, rebates, returns and other adjustments to sales. The change in the reserves for various sales adjustments may not be proportionally equal to the change in sales because of changes in both the product and the customer mix. Increased sales to wholesalers will generally require additional rebates. Incentives offered to secure sales vary from product to product. Provisions for estimated rebates and promotional and other credits are estimated based on historical payment experience, estimated customer inventory levels, and contract terms. Provisions for other customer credits, such as price adjustments, returns, and chargebacks require management judgment. Unlike branded innovator companies, Lannett does not use information about product levels in distribution channels from third-party sources, such as IMS Health, in estimating future returns and other credits.

**Chargebacks** The chargeback provision is based upon contracted prices with customers, and the accuracy of this provision is affected by changes in product sales mix and by the length of time it takes for wholesalers to move the products to the ultimate customers. This is considered the most significant and complex estimate used in the recognition of revenue.

The chargeback process begins when the Company sells its products through wholesalers to indirect customers such as independent pharmacies, managed care organizations, hospitals, nursing homes, and group purchasing organizations. The Company enters into agreements with its indirect customers to establish pricing for certain products. The indirect customers then select a wholesaler from which to receive the products at these contractual prices.

Upon the sale of a product to a wholesaler, the Company records the estimated chargeback provision based upon estimated indirect customers purchases and the contract prices with those indirect customers. Once the sale to the indirect customer occurs, the wholesaler requests a chargeback credit from the Company equal to the difference between the contractual price with the indirect customer and the wholesaler's invoice price, if the price sold to the indirect customer is lower than the direct price to the wholesaler. The provision for chargebacks is based on expected sell-through levels by the Company's wholesale customers to the indirect customers.

**Rebates** Rebates are offered to the Company's key customers and buying groups to promote customer loyalty and encourage product sales. These rebate programs provide customers with rebate credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. At the time of shipment, the Company estimates reserves for

rebates and other promotional credit programs based on the specific terms in each agreement. The reserve for rebates increases as sales to certain wholesale and retail customers increase. However, these rebate programs are tailored to the customers' individual programs. Hence, the reserve will depend on the mix of customers that comprise such rebate programs.

**Returns** Consistent with industry practice, the Company has a product returns policy that allows certain customers to return product within a specified period before and after the product's lot expiration date in exchange for a credit to be applied against future purchases. The Company's policy requires that the customer obtain pre-approval from the Company for any qualifying return. The Company estimates its provision for returns based on historical experience, business practices, and credit terms. While such experience has allowed for reasonable estimations in the past, historical returns may not always be an accurate indicator of future returns. The Company monitors the provisions for returns and makes adjustments when management believes that actual product returns may differ from established reserves. Generally, the reserve for returns increases as net sales increase. The reserve for returns is included in rebates and chargebacks payable on the balance sheet.

**Other Adjustments** Other adjustments consist primarily of price adjustments, also known as shelf stock adjustments, which are credits issued to reflect decreases in the selling prices of the Company's products that customers have remaining in their inventories at the time of the price reduction. Decreases in selling prices are discretionary decisions made by management in response to competitive market conditions. Amounts recorded for estimated shelf stock adjustments are based upon specified terms with direct customers, expected declines in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments are included in rebates and chargebacks payable on the balance sheet.

The following tables identify the reserves for each major category of revenue allowance and a summary of the activity for the nine months ended March 31, 2007 and 2006:

**For the nine months ended March 31, 2007**

Reserve Category	Chargebacks	Rebates	Returns	Other	Total
Reserve balance as of June 30, 2006	\$ 10,137,400	\$ 2,183,100	\$ 416,000	\$ 275,600	\$ 13,012,100
Actual credits issued related to sales recorded in prior fiscal years	(10,170,000)	(1,800,000)	(890,000)	(250,000)	(13,110,000)
Reserves or (reversals) charged during Fiscal 2007 related to sales recorded in prior fiscal years		(300,000)	460,000		160,000
Reserves charged to net sales during fiscal 2007 related to sales recorded in fiscal 2007	24,340,700	8,832,300	986,400	1,033,100	35,192,500
Actual credits issued related to sales recorded in Fiscal 2007	(17,065,500)	(5,122,200)	(954,700)	(265,000)	(23,407,400)
Reserve balance as of March 31, 2007	\$ 7,242,600	\$ 3,793,200	\$ 17,700	\$ 793,700	\$ 11,847,200

**For the nine months ended March 31, 2006**

Reserve Category	Chargebacks	Rebates	Returns	Other	Total
Reserve Balance as of June 30, 2005	\$ 7,999,700	\$ 1,028,800	\$ 1,692,000	\$ 29,500	\$ 10,750,000
Actual credits issued related to sales recorded in prior fiscal years	(7,720,000)	(1,450,900)	(1,264,800)	(27,200)	(10,462,900)
Reserves or (reversals) charged during Fiscal 2006 related to sales recorded in prior fiscal years					

Edgar Filing: LANNETT CO INC - Form 10-Q/A

Reserves charged to net sales during fiscal 2006 related to sales recorded in fiscal 2006	21,207,000	4,085,800	297,300	912,700	26,502,800
Actual credits issued related to sales recorded in Fiscal 2006	(8,612,100)	(2,313,400)	(273,400)	(892,800)	(12,091,700)
Reserve Balance as of March 31, 2006	\$ 12,874,600	\$ 1,350,300	\$ 451,100	\$ 22,200	\$ 14,698,200

**Accounts Receivable** - The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of current credit information. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer credit and collection issues that have been identified. While such credit losses have historically been within both the Company's expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past. This provision is \$250,000 at March 31, 2007 and June 30, 2006.

**Inventories** - The Company values its inventory at the lower of cost (determined by the first-in, first-out method) or market, regularly reviews inventory quantities on hand, and records a provision for excess and obsolete inventory based primarily on estimated forecasts of product demand and production requirements. The Company's estimates of future product demand may prove to be inaccurate, in which case it may have understated or overstated the provision required for excess and obsolete inventory. In the future, if the Company's inventory is determined to be overvalued, the Company would be required to recognize such costs in cost of goods sold at the time of such determination. Likewise, if inventory is determined to be undervalued, the Company may have recognized excess cost of goods sold in previous periods and would be required to recognize such additional operating income at the time of sale.

**Property, Plant and Equipment** - Property, plant and equipment are stated at cost. Depreciation is provided for by the straight-line and accelerated methods over estimated useful lives of the assets.

**Investment Securities** - All of the Company's marketable debt securities are classified as available-for-sale and recorded at fair value, based on quoted market prices.

**Fair Value of Financial Instruments** - The Company's financial instruments consist primarily of cash and cash equivalents, trade receivables, trade payables and debt instruments. The carrying values of cash and cash equivalents, trade receivables, and trade payables are considered to be representative of their respective fair values. The Company's debt instruments are fixed rate, with a lower interest rate than the prevailing market rates. The Company has been able to obtain favorable rates through Philadelphia and Pennsylvania Industrial Development Authorities.

**Deferred Debt Acquisition Costs** - Costs incurred in connection with obtaining financing are amortized by the straight-line method over the term of the loan arrangements. These costs are included in interest expense in the Consolidated Statements of Income. Amortization expense for debt acquisition costs for the three months ended March 31, 2007 and 2006 was approximately \$9,000 in both periods, and for the nine months ended March 31, 2007 and 2006 was approximately \$27,000 and \$ 51,000, respectively

**Shipping and Handling Costs** - The cost of shipping products to customers is recognized at the time the products are shipped, and is included in **Cost of Sales**.

**Research and Development** - Research and development expenses are charged to operations as incurred.

**Advertising Costs** - The Company charges advertising costs to operations as incurred.

**Income Taxes** - The Company uses the liability method specified by Statement of Financial Accounting Standards No. 109 (FAS 109), *Accounting for Income Taxes*. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense/(benefit) is the result of changes in deferred tax assets and liabilities.

**Segment Information** The Company reports segment information in accordance with Statement of Financial Accounting Standard No. 131 (FAS 131), *Disclosures about Segments of an Enterprise and Related Information*. The Company operates one business segment – generic pharmaceuticals – and one reporting segment. In accordance with FAS 131, the Company aggregates its financial information for all products and reports on one operating segment. The Company’s products contain various active pharmaceutical ingredients aimed at treating a diverse range of medical indications. The following table identifies the Company’s approximate net product sales by medical indication for the three and nine months ended March 31, 2007 and 2006:

	For the three Months Ended March 31,		For the nine Months Ended March 31,	
	2007	2006	2007	2006
Migraine Headache	\$ 2,851,000	\$ 2,137,000	\$ 8,013,000	\$ 8,656,000
Epilepsy	2,071,000	3,240,000	6,544,000	9,929,000
Heart Failure	1,029,000	1,620,000	3,532,000	4,886,000
Thyroid Deficiency	8,338,000	4,787,000	26,617,000	12,504,000
Antibiotics	5,310,000	2,074,000	17,512,000	3,672,000
Other	704,000	1,879,000	2,969,000	4,960,000
	\$ 20,303,000	\$ 15,737,000	\$ 65,187,000	\$ 44,607,000

**Concentration of Market and Credit Risk** Five of the Company’s products, defined as generics containing the same active ingredient or combination of ingredients, accounted for approximately 39%, 23%, 15%, 10%, and 5%, respectively, of net sales for the three months ended March 31, 2007. The same five products accounted for 26%, 3%, 13%, 21%, and 10%, respectively, of net sales for the three months ended March 31, 2006; 38%, 23%, 11%, 10% and 5% of net sales for the nine months ended March 31, 2007; 23%, 3%, 18%, 22% and 11%, respectively, of net sales for the nine months ended March 31, 2006.

Credit terms are offered to customers based on evaluations of the customers’ financial condition. Generally, collateral is not required from customers. Accounts receivable payment terms vary and are stated in the financial statements at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and the industry as a whole. The Company writes-off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

**Stock Options** - In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 123 (R), *Share-Based Payment* (SFAS 123(R)). This standard is a revision of SFAS 123, *Accounting for Stock-Based Compensation* and supersedes Accounting Principles Board Opinion (APB) No. 25, *Accounting for Stock Issued to Employees*. SFAS 123(R) addresses the accounting for share-based compensation in which we receive employee services in exchange for our equity instruments. Under the standard, we are required to recognize compensation cost for share-based compensation issued to or purchased by employees, net of estimated forfeitures, under share-based compensation plans using a fair value method.

At March 31, 2007, the Company had two stock-based employee compensation plans. Prior to July 1, 2005, the Company accounted for those plans under the recognition and measurement provisions of APB 25, and related Interpretations, as permitted by SFAS 123. Effective July 1, 2005, the Company adopted the fair value recognition provisions of SFAS 123(R), using the modified-prospective-transition method.



Edgar Filing: LANNETT CO INC - Form 10-Q/A

Under this method, the Company is required to record compensation expense for all awards granted after the date of adoption and for the unvested portion of previously granted awards that remained outstanding as of the beginning of the period of adoption. The Company measures share-based compensation cost using the Black-Scholes option pricing model. The following table presents the weighted average assumptions used to estimate fair values of the stock options granted during the nine months ended March 31, 2007:

Risk-free interest rate	4.74%
Expected volatility	59%
Expected dividend yield	0.0%
Expected term (in years)	5.00
Weighted average fair value	\$ 4.36

There were no options issued during the three months ended March 31, 2007. Approximately 354,000 options were issued during the nine months ended March 31, 2007. This compares to approximately 25,000 and 109,000 options issued during the three and nine months ended March 31, 2006. There were 375 shares under option that were exercised in the nine months ended March 31, 2007, resulting in proceeds of \$281 to the Company. No options were exercised in the three months ended March 31, 2007. There were 1,000 shares under option that were exercised in the three and nine month periods ended March 31, 2006, resulting in proceeds of \$4,633 to the Company.

Expected volatility is based on the historical volatility of the price of our common shares since active trading commenced on the American Stock Exchange in April 2002. We use historical information to estimate expected term within the valuation model. The expected term of awards represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Compensation cost is recognized using a straight-line method over the vesting or service period and is net of estimated forfeitures.

The forfeiture rate assumption is the estimated annual rate at which unvested awards are expected to be forfeited during the vesting period. This assumption is based on our historical forfeiture rate. Periodically, management will assess whether it is necessary to adjust the estimated rate to reflect changes in actual forfeitures or changes in expectations. For example, adjustments may be needed if, historically, forfeitures were affected mainly by turnover that resulted from a business restructuring that is not expected to recur. The increase in the forfeiture rate from 3% at March 31, 2006 to 5.0% at March 31, 2007 is an adjustment made to account for recent turnover at manager levels. As the Company continues to grow, this rate is likely to change to match such changes in growth businesses. Under the provisions of FAS 123R, the Company will incur additional expense if the actual forfeiture rate is lower than originally estimated. A recovery of prior expense will be recorded if the actual rate is higher than originally estimated.

The following table presents all share-based compensation costs recognized in our statements of income as part of selling, general and administrative expenses:

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2007 (restated)	2006	2007 (restated)	2006
Method used to account for share-based compensation	Fair Value	Fair Value	Fair Value	Fair Value
Share-based compensation under SFAS 123(R)	\$ 332,821	\$ 386,088	\$ 856,868	\$ 1,072,071
Tax benefit	\$ 46,940	\$ 79,350	\$ 140,821	\$ 238,050



Edgar Filing: LANNETT CO INC - Form 10-Q/A

Options outstanding that have vested and are expected to vest as of March 31, 2007 are as follows:

	Awards	Weighted-Average Exercise Price	Aggregate Intrinsic Value	Weighted Average Remaining Contractual Life
Options vested	611,052	\$ 11.24	\$ 23,425	6.6
Options expected to vest	495,310	\$ 7.19	\$ 68,367	9.0
Total vested and expected to vest	1,106,362	\$ 9.37	\$ 91,792	7.7

A summary of award activity under the Plans as of March 31, 2007 and 2006, and changes during the nine months then ended, is presented below:

	Awards	Weighted-Average Exercise Price	Aggregate Intrinsic Value	Weighted Average Remaining Contractual Life
Outstanding at July 1, 2006	792,003	\$ 10.89		7.3
Granted	353,783	\$ 6.02		
Exercised	375	\$ 0.75	\$ 2,063	
Forfeited or expired	12,980	\$ 10.56		
Outstanding at March 31, 2007	1,132,431	\$ 9.38	\$ 95,390	7.7
Outstanding at March 31, 2007 and not yet vested	521,379	\$ 7.19	\$ 71,965	9.0
Exercisable at March 31, 2007	611,052	\$ 11.24	\$ 23,425	6.6

	Awards	Weighted-Average Exercise Price	Aggregate Intrinsic Value	Weighted Average Remaining Contractual Life
Outstanding at July 1, 2005	857,108	\$ 13.72		
Granted	108,500	\$ 6.07		
Exercised	1,000	\$ 4.63		
Forfeited or expired				
Outstanding at March 31, 2006	964,608	\$ 11.25	\$ 375,460	7.6
Outstanding at March 31, 2006 and not yet vested	388,721	\$ 11.40	\$ 250,605	8.0
Exercisable at March 31, 2006	575,887	\$ 11.14	\$ 124,855	7.4

As of March 31, 2007, there was approximately \$1,429,000 of total unrecognized compensation cost related to nonvested share-based compensation awards granted under the Plans. That cost is expected to be recognized over a weighted average period of 1.6 years. As of March 31, 2006, there was approximately \$1,568,000 of total unrecognized compensation cost related to nonvested share-based compensation awards granted under the Plans.

**Unearned Grant Funds** The Company records all grant funds received as a liability until the Company fulfills all the requirements of the grant funding program.

**Note 4. New Accounting Standards**

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (Including an amendment of FASB Statement No. 115) (SFAS 159). This Statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. The objective is to improve financial reporting by providing entities with

the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS 159 is expected to expand the use of fair value measurement, which is consistent with the Financial Accounting Standards Board's long-term measurement objective for accounting for financial instruments. This statement also establishes presentation and disclosure requirements designed to facilitate comparisons between entities that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 does not affect any existing accounting literature that requires certain assets and liabilities to be carried at fair value. This statement does not establish requirements for recognizing and measuring dividend income, interest income, or interest expense. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007, which, in the Company's case, is the fiscal year beginning July 1, 2008. This statement does not eliminate disclosure requirements included in other accounting standards, including requirements for disclosure about fair value measurements included in FASB Statement No. 157 Fair Value Measurements, and No. 107 Disclosure about Fair Value of Financial Instruments. The Company has not yet completed assessing the impact this standard will have on its financial statements and results of operations.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157). This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this Statement does not require any new fair value measurements. However, for some entities, the application of this Statement will change current practice. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company will be required to adopt the guidance of SFAS 157 beginning July 1, 2008. The Company has not completed its study of the effects of adopting this standard.

In July 2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48), to clarify the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS 109, Accounting for Income Taxes. Effective for fiscal years beginning after December 15, 2006, FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company will be required to adopt the guidance of FIN 48 beginning July 1, 2007. While earlier adoption is permitted by the FASB, the Company has not yet completed its evaluation of the impact that adoption of FIN 48 will have on its financial statements.

In September 2006, the SEC staff issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. SAB 108 was issued to provide consistency between how registrants quantify financial statement misstatements.

Historically, there have been two widely-used methods for quantifying the effects of financial statement misstatements. These methods are referred to as the roll-over and iron curtain method. The roll-over method quantifies the amount by which the current year income statement is misstated. Exclusive reliance on an income statement approach can result in the accumulation of errors on the balance sheet that may not have been material to any individual income statement, but which may misstate one or more balance sheet accounts. The iron curtain method quantifies the error as the cumulative amount by which the current year balance sheet is misstated. Exclusive reliance on a balance sheet approach can result in disregarding the effects of errors in the current year income statement that results from the correction of an error existing in previously issued financial statements. We currently use the roll-over method for quantifying identified financial statement misstatements.

SAB 108 established an approach that requires quantification of financial statement misstatements based on the effects of the misstatement on each of the Company's financial statements and the related financial statement disclosures. This approach is commonly referred to as the dual approach because it requires quantification of errors under both the roll-over and iron curtain methods.



SAB 108 allows registrants to initially apply the dual approach either by (1) retroactively adjusting prior financial statements as if the dual approach had always been used or by (2) recording the cumulative effect of initially applying the dual approach as adjustments to the carrying values of assets and liabilities as of July 1, 2006 with an offsetting adjustment recorded to the opening balance of retained earnings. Use of this cumulative effect transition method requires detailed disclosure of the nature and amount of each individual error being corrected through the cumulative adjustment and how and when it arose.

The effective date for SAB 108 is the first fiscal year ending after November 15, 2006. For Lannett, SAB 108 is effective immediately, for the fiscal year ending June 30, 2007. The Company has not yet determined the effect of adopting this guidance, but will be completing an analysis on the effect of this guidance before the end of the fiscal year.

**Note 5. Inventories**

The Company values its inventories at the lower of cost (determined by the first-in, first-out method) or market, regularly reviews inventory quantities on hand, and records a provision for excess and obsolete inventory based primarily on estimated forecasts of product demand and production requirements. Inventories consist of:

	<b>March 31, 2007</b>		<b>June 30, 2006</b>
	<b>(restated)</b>		
Raw Material	\$ 3,866,139	\$	5,143,714
Work-in-process	1,119,714		1,438,794
Finished Goods	7,139,322		4,511,274
Packaging Supplies	286,357		382,721
	\$ 12,411,532	\$	11,476,503

The preceding amounts are net of inventory reserves of \$1,179,188 and \$1,054,499 at March 31, 2007 and June 30, 2006, respectively.

**Note 6. Property, Plant and Equipment**



Edgar Filing: LANNETT CO INC - Form 10-Q/A

Property, plant and equipment are stated at cost. Depreciation is provided for by the straight-line and accelerated methods over estimated useful lives of the assets. Depreciation expense for the three months ended March 31, 2007 and 2006 was approximately \$690,000 and \$541,000, respectively. Depreciation expense for the nine months ended March 31, 2007 and 2006 was approximately \$1,982,000 and \$1,580,000, respectively. Property, plant and equipment consist of the following:

	Useful Lives	March 31, 2007	June 30, 2006
Land		\$ 233,414	\$ 233,414
Building and improvements	10 - 39 years	11,999,630	10,612,954
Machinery and equipment	5 - 10 years	18,784,259	17,109,279
Furniture and fixtures	5 - 7 years	837,262	826,703
		\$ 31,854,565	\$ 28,782,350

**Note 7. Investment Securities - Available-for-Sale**

The Company's investment securities consist of marketable debt securities, primarily in U.S. government and agency obligations, and a \$500,000 equity investment in an Active Pharmaceutical Ingredient ( API ) provider. All of the Company's marketable debt securities are classified as available-for-sale and recorded at fair value, based on quoted market prices. The Company accounts for its investment in the API provider at cost. Unrealized holding gains and losses are recorded, net of any tax effect, as a separate component of accumulated other comprehensive income. No gains or losses on marketable debt securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. There were no securities determined by management to be other-than-temporarily impaired for the nine month period ended March 31, 2007.

The amortized cost, gross unrealized gains and losses, and fair value of the Company's available-for-sale securities are summarized as follows:

<b>March 31, 2007</b>					
<b>Available-for-Sale</b>					
	<b>Amortized Cost</b>	<b>Gross Unrealized</b>			<b>Fair Value</b>
		<b>Gains</b>	<b>Losses</b>		
U.S. Government Agency	\$ 2,202,811	\$ 11,555	\$ (25,795)	\$	2,188,571
Asset-Backed Securities	1,139,520	15	(48,012)		1,191,523
Other Investments	500,000				500,000
	<b>\$ 3,842,331</b>	<b>\$ 11,570</b>	<b>\$ (73,807)</b>	<b>\$</b>	<b>3,780,094</b>

<b>June 30, 2006</b>					
<b>Available-for-Sale</b>					
	<b>Amortized Cost</b>	<b>Gross Unrealized</b>	<b>Gross Unrealized</b>		<b>Fair Value</b>
		<b>Gains</b>	<b>Losses</b>		
U.S. Government Agency	\$ 3,593,368	\$ 15	\$ (67,510)	\$	3,525,873
Asset-Backed Securities	1,648,981	63	(53,308)		1,595,736
Other Investments	500,000				500,000
	<b>\$ 5,742,349</b>	<b>\$ 78</b>	<b>\$ (120,818)</b>	<b>\$</b>	<b>5,621,609</b>

The amortized cost and fair value of the Company's current available-for-sale securities by contractual maturity at March 31, 2007 are summarized as follows:

<b>March 31, 2007</b>			
<b>Available for Sale</b>			
	<b>Amortized</b>		<b>Fair</b>
	<b>Cost</b>		<b>Value</b>
Due in one year or less	\$ 201,540	\$	198,386
Due after one year through five years	2,699,394		2,685,135
Due after five years through ten years	287,527		280,316
Due after ten years	653,870		616,257
	<b>\$ 3,842,331</b>	<b>\$</b>	<b>3,780,094</b>

Edgar Filing: LANNETT CO INC - Form 10-Q/A

The Company uses the specific identification method to determine the cost of securities sold. There were no securities held from a single issuer that represented more than 15% of shareholders' equity.

The table below indicates the length of time individual securities have been in a continuous unrealized loss position as of March 31, 2007:

Edgar Filing: LANNETT CO INC - Form 10-Q/A

Description of Securities	Number of Securities	Less than 12 months		March 31, 2007 12 months or longer		Total	
		Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
U.S. Government Agency	4	39,508	(16)	718,691	(25,779)	758,199	(25,795)
Asset-Backed Securities	13	47,248	(911)	995,891	(47,101)	1,043,139	(48,012)
Total tempory impaired investment securities	17	\$ 86,756	\$ (927)	\$ 1,714,581	\$ (72,880)	\$ 1,801,337	\$ (73,807)

The investment securities shown above currently have fair values less than amortized cost and therefore contain unrealized losses. The Company has evaluated these securities and has determined that the decline in value is not related to any company or industry specific event. At March 31, 2007, there were approximately 17 out of 27 investment securities with unrealized losses. The Company anticipates full recovery of amortized costs with respect to these securities at maturity or sooner in the event of a more favorable market interest rate environment. Realized gains and losses from sale of investment securities have been immaterial for the three and nine month periods ended March 31, 2007 and 2006.

**Note 8. Note Receivable (restated)**

A loan agreement with Cody Laboratories, Inc. ( Cody Labs ) was entered in July 2005. On April 10, 2007, subsequent to March 31, 2007, the Company acquired all remaining outstanding stock in Cody Labs, in exchange for this note receivable plus other consideration. Terms of the acquisition are detailed more fully in Note 18 Subsequent Event. In the original loan agreement, the Company loaned Cody Labs \$2.0 million to finance general business activities. Additional loans had been made to Cody Labs since the loan was initiated. The balance owed by Cody was approximately \$10.5 million at March 31, 2007. The initial \$2.0 million note receivable was backed by a promissory note and a security interest in substantially all of Cody Labs assets. Interest on this principal balance was stated at 10% per annum for the first three years. The agreement called for Cody Labs to pay all interest that had accrued and was due and owing on the initial note on the first, second and third anniversary date of this Agreement. Cody Labs requested an extension to the first interest payment, which was due in July 2006. Cody Labs made this interest payment in January 2007.

The Company determined this note was impaired on March 31, 2007. A total of \$11.7 million advanced to Cody Labs was composed of \$10.5 million note receivable and \$1.2 million in prepayments, which were included in other assets. A valuation of Cody Labs as of the acquisition date, April 10, 2007, was obtained. From that valuation, management concluded that, as of March 31, 2007, the net assets of Cody Labs were less than the note receivable and prepayment amounts outstanding. The impairment of \$7,775,890 is the difference between the amounts outstanding from Cody Labs and the net assets of Cody Labs as of March 31, 2007.

**Note 9. Bank Line of Credit**

The Company has a \$3,000,000 line of credit from Wachovia Bank, N.A. that bears interest at the prime interest rate less 0.25% (8.0% at March 31, 2007). The line of credit was renewed and extended to November 30, 2007. At March 31, 2007 and 2006, the Company had \$0 outstanding under the line of credit. The line of credit is collateralized by substantially all of the Company s assets. The Company currently has no plans to borrow under this line of credit.

**Note 10. Unearned Grant Funds**

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

In July 2004, the Company received \$500,000 of grant funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development. The grant funding program requires the Company to use the funds for machinery and equipment located at their Pennsylvania locations, hire an additional 100 full-time employees by June 30, 2006, operate its Pennsylvania locations a minimum of five years and meet certain matching investment requirements. If the Company fails to comply with any of the requirements above, the Company would be liable to repay the full amount of the grant funding (\$500,000). The Company records the unearned grant funds as a liability until the Company complies with all of the requirements of

the grant funding program. On a quarterly basis, the Company will monitor its progress in fulfilling the requirements of the grant funding program and will determine the status of the liability. As of March 31, 2007, the grant funding is recognized as a short term liability under the caption of Unearned Grant Funds, since the Company has met approximately 50% of the requirement to add 100 full-time employees. However, the Company is requesting an extension of this obligation to add 100 employees, since the other requirement related to use of funds has been met already, and the requirement to operate its Pennsylvania locations is still ongoing.

#### **Note 11. Long-Term Debt**

Long-term debt consists approximately of the following:

	March 31, 2007	June 30, 2006
PIDC Regional Development Center, LP III loan	\$ 4,500,000	\$ 4,500,000
Pennsylvania Industrial Development Authority loan	1,170,000	1,222,000
Pennsylvania Department of Community & Economic Development loan	413,000	476,000
Tax-exempt bond loan (PAID)	905,000	956,000
Equipment loan	802,000	1,043,000
Total debt	7,790,000	8,197,000
Less current portion	597,000	547,000
Long term debt	\$ 7,193,000	\$ 7,650,000

On December 13, 2005, the Company refinanced \$5,750,000 of its debt through the Philadelphia Industrial Development Corporation (PIDC) and the Pennsylvania Industrial Development Authority (PIDA). With the proceeds from the refinancing, the Company paid off its Mortgage and Construction Loan, as well as a portion of the Equipment loan. These loans were with Wachovia Bank. The Company financed \$4,500,000 through the Immigrant Investor Program (PIDC Regional Center, LP III). The Company will pay a bi-annual interest payment at a rate equal to two and one-half percent per annum. The outstanding principal balance shall be due and payable 5 years (60 months) from January 1, 2006. The remaining \$1,250,000 is financed through the PIDA Loan. The Company is required to make equal payments each month for 180 months starting February 1, 2006 with interest of two and three-quarter percent per annum. The PIDA Loan has approximately \$1,170,000 outstanding as of March 31, 2007, and \$70,497 is currently due; none of the PIDC Loan is currently due.

An additional \$500,000 was financed through the Pennsylvania Department of Community and Economic Development Machinery and Equipment Loan Fund. The Company is required to make equal payments for 60 months starting May 1, 2006 with interest of 2.75% per annum. As of March 31, 2007, approximately \$413,000 is outstanding, and \$96,995 is currently due.

In April 1999, the Company entered into a loan agreement (the Agreement) with a governmental authority, the Philadelphia Authority for Industrial Development (the Authority or PAID), to finance future construction and growth projects of the Company. The Authority issued \$3,700,000 in tax-exempt variable rate demand and fixed rate revenue bonds to provide the funds to finance such growth projects pursuant to a trust indenture (the Trust Indenture). A portion of the Company's proceeds from the bonds was used to pay for bond issuance costs of approximately \$170,000. The Trust Indenture requires that the Company repay the Authority loan through installment payments beginning in

Edgar Filing: LANNETT CO INC - Form 10-Q/A

May 2003 and continuing through May 2014, the year the bonds mature. The bonds bear interest at the floating variable rate determined by the organization responsible for selling the bonds

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

(the remarketing agent). The interest rate fluctuates on a weekly basis. The effective interest rate at March 31, 2007 was 3.8%. At March 31, 2007, the Company has approximately \$904,000 outstanding on the Authority loan, of which approximately \$109,000 is classified as currently due. The remainder is classified as a long-term liability. In April 1999, an irrevocable letter of credit of \$3,770,000 was issued by Wachovia Bank, National Association (Wachovia) to secure payment of the Authority Loan and a portion of the related accrued interest. At March 31, 2007, no portion of the letter of credit has been utilized.

The Equipment Loan consists of a term loan with a maturity of five years. The Company, as part of the 2003 Loan Financing agreement with Wachovia, is required to make equal payments of principal and interest. As of March 31, 2007, the Company has outstanding approximately \$802,000 under the Equipment Loan, of which approximately \$321,000 is classified as currently due.

The financing facilities under the 2003 Loan Financing, of which only the Equipment Loan is left, bear interest at a variable rate equal to the LIBOR rate plus 150 basis points. The LIBOR rate is the rate per annum, based on a 30-day interest period, quoted two business days prior to the first day of such interest period for the offering by leading banks in the London interbank market of dollar deposits. As of March 31, 2007, the interest rate for the 2003 Loan Financing (of which only the Equipment loan remains) was 6.82%.

The Company has executed Security Agreements with Wachovia, PIDA and PIDC in which the Company has agreed to pledge substantially all of its assets to collateralize the amounts due.

The terms of the Equipment loan require that the Company meet certain financial covenants and reporting standards, including the attainment of standard financial liquidity and net worth ratios. As of March 31, 2007, the Company has complied with such terms, and successfully met its financial covenants.

Long-term debt amounts due, for the twelve month periods ended March 31 are approximately as follows:

12 month period ended March 31,	Amount payable to Institution
2007	\$ 597,000
2008	607,000
2009	462,000
2010	4,810,000
2011	214,000
Thereafter	1,100,000
	\$ 7,790,000

### **Note 12. Income Taxes**

The Company uses the liability method specified by Statement of Financial Accounting Standards No. 109 (FAS 109), *Accounting for Income Taxes*. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense is the result of

changes in deferred tax assets and liabilities.

The (benefit) provision for federal, state and local income taxes for the three month period ended March 31, 2007 and 2006 was \$(818,807) (restated, see Note 2) and \$856,402, respectively, with an effective tax rate of 41%. The provision for federal, state and local income taxes for the nine month period ended March 31, 2007 and 2006 was \$685,791 (restated, see Note2) and \$2,752,335, respectively, with effective tax rates of (18.7%) and 40%, respectively.

**Note 13. Earnings Per Share**

Statement of Financial Accounting Standards No. 128 (FAS 128), Earnings Per Share, requires the presentation of basic and diluted earnings per share on the face of the Company's consolidated statement of income and a reconciliation of the computation of basic earnings per share to diluted earnings per share. Basic earnings per share exclude the dilutive impact of common stock equivalents and are computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share include the effect of potential dilution from the exercise of outstanding common stock equivalents into common stock using the treasury stock method. Earnings per share amounts for all periods presented have been calculated in accordance with the requirements of FAS 128. A reconciliation of the Company's basic and diluted earnings per share follows:

	2007		Three Months Ended March 31		2006	
	Net Income (Numerator) (restated, see Note 2)	Shares (Denominator)	Net Income (Numerator)	Shares (Denominator)	Net Income (Numerator)	Shares (Denominator)
Basic (loss) earnings per share factors	\$ (6,607,359)	24,164,385	\$ 1,254,659	24,135,723		
Effect of dilutive stock options						65,439
Diluted (loss) earnings per share factors	\$ (6,607,359)	24,164,385	\$ 1,254,659	24,201,162		
Basic (loss) earnings per share	\$ (0.27)		\$ 0.05			
Diluted (loss) earnings per share	\$ (0.27)		\$ 0.05			

The number of anti-dilutive shares that have been excluded in the computation of diluted earnings per share for the three months ended March 31, 2007 and 2006 were 1,132,431 and 760,358 respectively.

	2007		Nine Months Ended March 31		2006	
	Net Income (Numerator) (restated, see Note 2)	Shares (Denominator)	Net Income (Numerator)	Shares (Denominator)	Net Income (Numerator)	Shares (Denominator)
Basic (loss) earnings per share factors	\$ (4,354,162)	24,155,556	\$ 4,123,279	24,126,588		
Effect of dilutive stock options						47,610
Diluted (loss) earnings per share factors	\$ (4,354,162)	24,155,556	\$ 4,123,279	24,174,198		
Basic (loss) earnings per share	\$ (0.18)		\$ 0.17			
Diluted (loss) earnings per share	\$ (0.18)		\$ 0.17			

The number of anti-dilutive shares that have been excluded in the computation of diluted earnings per share for the nine months ended March 31, 2007 and 2006 were 1,132,431 and 760,358, respectively.

**Note 14. Comprehensive Income**

The Company's other comprehensive loss is comprised of unrealized losses on investment securities classified as available-for-sale. The components of comprehensive income and related taxes consisted of the following as of March 31, 2007 and 2006:

	For the Three Months Ended		For the Nine Months Ended	
	3/31/2007 restated	3/31/2006	3/31/2007 restated	3/31/2006
<i>Other Comprehensive (Loss) Income:</i>				
Unrealized Holding Gain (Loss) on Securities	\$ 3,173	\$ (19,244)	\$ 58,503	\$ (100,933)
Tax at effective rate	(1,269)	7,698	(23,401)	41,533
Total Unrealized Gain (Loss) on Securities, Net	1,904	(11,546)	35,102	(59,400)
Total Other Comprehensive Income (Loss)	1,904	(11,546)	35,102	(59,400)
Net (loss) income (restated)	(6,607,359)	1,254,659	(4,354,162)	4,123,279
Total Comprehensive (Loss) Income	\$ (6,605,455)	\$ 1,243,113	\$ (4,319,060)	\$ 4,063,879

**Note 15. Related Party Transactions**

The Company had sales of approximately \$624,000 and \$900,000 during the nine months ended March 31, 2007 and 2006, respectively, to a distributor (the related party) owned by Jeffrey Farber. Mr. Farber is a member of the Board of Directors, as well as the son of William Farber, who is the Chairman of the Board and principal shareholder of the Company. Accounts receivable includes amounts due from the related party of approximately \$171,000 and \$171,000 at March 31, 2007 and 2006, respectively. In management's opinion, the terms of these transactions were not more favorable to the related party than they would have been to a non-related party.

The Company had sales of approximately \$298,000 during the nine months ended March 31, 2007 to a distributor of pharmaceutical products. The Company currently owns 33% of this distributor. The cost of goods sold to this distributor amounted to \$144,000 for the nine month period ending March 31, 2007. The Company has recorded no investment in this business, due to the fact that no consideration has been paid in exchange for the ownership.

In January 2005, Lannett Holdings, Inc. entered into an agreement in which the Company purchased for \$100,000 and future royalty payments the proprietary rights to manufacture and distribute a product for which Pharmeral, Inc. owns the ANDA. This agreement is subject to the Company's ability to obtain FDA approval to use the proprietary rights. In the event that an approval can not be obtained, Pharmeral, Inc. must repay the \$100,000 to the Company. Accordingly, the Company has treated this payment as a prepaid asset. Arthur Bedrosian, President of the Company, Inc. was formerly the President and Chief Executive Officer and currently owns 100% of Pharmeral, Inc. This transaction was approved by the Board of Directors of the Company and in their opinion the terms were not more favorable to the related party than they would have been to a non-related party.

**Note 16. Material Contract with Supplier**

Jerome Stevens Pharmaceuticals agreement:

The Company's primary finished product inventory supplier is Jerome Stevens Pharmaceuticals, Inc. (JSP), in Bohemia, New York. Purchases of finished goods inventory from JSP accounted for approximately 32% and 52% of the Company's inventory purchases during the three and nine month periods ended March 31, 2007. JSP accounted for 68% and 62% of finished goods inventory purchases during the three and nine month periods ended March 31, 2006. On March 23, 2004, the Company entered into an agreement with JSP for the exclusive distribution rights in the United States to the current line of JSP products, in exchange for four million (4,000,000) shares of the Company's common stock. The JSP products covered under the agreement included Butalbital, Aspirin, Caffeine with Codeine Phosphate capsules, Digoxin tablets and

Edgar Filing: LANNETT CO INC - Form 10-Q/A

Levothyroxine Sodium tablets, sold generically and under the brand name Unithroid®. The term of the agreement is ten years, beginning on March 23, 2004 and continuing through March 22, 2014. Both Lannett and JSP have the right to terminate the contract if one of the parties does not cure a material breach of the contract within thirty (30) days of notice from the non-breaching party.

During the term of the agreement, the Company is required to use commercially reasonable efforts to purchase minimum dollar quantities of JSP's products being distributed by the Company. The minimum quantity to be purchased in the first year of the agreement is \$15 million. Thereafter, the minimum quantity to be purchased increases by \$1 million per year up to \$24 million for the last year of the ten-year contract. The Company has met the minimum purchase requirement for the first two years of the contract, but there is no guarantee that the Company will be able to continue to do so in the future. If the Company does not meet the minimum purchase requirements, JSP's sole remedy is to terminate the agreement.

Under the agreement, JSP is entitled to nominate one person to serve on the Company's Board of Directors (the Board) provided, however, that the Board shall have the right to reasonably approve any such nominee in order to fulfill its fiduciary duty by ascertaining that such person was suitable for membership on the board of a publicly traded corporation. Suitability is determined by, but not limited to, the requirements of the Securities and Exchange Commission, the American Stock Exchange, and other applicable laws, including the Sarbanes-Oxley Act of 2002. As of March 31, 2007, JSP has not exercised the nomination provision of the agreement. The agreement was included as an Exhibit in the Current Report on Form 8-K filed by the Company on May 5, 2004, as subsequently amended.

Management determined that the intangible product rights asset created by this agreement was impaired as of March 31, 2005. Refer to Form 10-K dated June 30, 2006, Note 1 Intangible Assets for additional disclosure and discussion of this impairment.

Other agreements:

In August 2005, the Company signed an agreement with a finished goods provider to purchase, at fixed prices, and distribute a certain generic pharmaceutical product in the United States. Purchases of finished goods inventory from this provider accounted for approximately 25% and 20% of the Company's inventory purchases during the three and nine month periods ended March 31, 2007. This provider accounted for 7% and 9% of the Company's inventory purchases during the three and nine month periods ended March 31, 2006. The term of the agreement is three years, beginning on August 22, 2005 and continuing through August 21, 2008.

During the term of the agreement, the Company has committed to provide a rolling twelve month forecast of the estimated Product requirements to this provider. The first three months of the rolling twelve month forecast are binding and constitute a firm order. To date, all commitments arising from the agreement have been met.

#### **Note 17. Contingencies**

The Company monitors its compliance with all environmental laws. Any compliance costs which may be incurred are contingent upon the results of future site monitoring and will be charged to operations when incurred. No monitoring costs were incurred during the three month and nine month periods ended March 31, 2007 and 2006.

The Company is currently engaged in several civil actions as a co-defendant with many other manufacturers of Diethylstilbestrol (DES), a synthetic hormone. Prior litigation established that the Company's pro rata share of any liability is less than one-tenth of one percent. The Company was represented in many of these actions by the insurance company with which the Company maintained coverage during the time period that damages were alleged to have occurred. The insurance company denies coverage for actions alleging involvement of the Company

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

filed after January 1, 1992. With respect to these actions, the Company paid nominal damages or stipulated to its pro rata share of any liability. The Company has either settled or is currently defending over 500 such claims. At this time, management is unable to estimate a range of loss, if any, related to these actions. Management believes that the outcome of these cases will not have a material adverse impact on the financial position or results of operations of the Company.

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

In addition to the matters reported herein, the Company is involved in litigation which arises in the normal course of business. In the opinion of management, the resolution of these lawsuits will not have a material adverse effect on the consolidated financial position or results of operations.

The following table illustrates Lannett's future contractual obligations as of March 31, 2007:

	Total	Less than 1 year	1-3 years	3-5 years	more than 5 years
Long-Term Debt	\$ 7,790,000	\$ 597,000	\$ 1,069,000	\$ 5,024,000	\$ 1,100,000
Operational Leases	1,711,700	368,500	770,600	572,600	-0-
Purchase Obligations	147,000,000	18,000,000	39,000,000	43,000,000	47,000,000
Interest on Obligations					
<b>Total</b>	<b>\$ 156,501,700</b>	<b>\$ 18,965,500</b>	<b>\$ 40,839,600</b>	<b>\$ 48,596,600</b>	<b>\$ 48,100,000</b>

### **Note 18. Subsequent Event**

On April 10, 2007, the Company acquired Cody Laboratories, Inc. ( Cody Labs ) by purchasing all of the remaining shares of common stock of Cody Labs. The Company initially acquired a 12.5% direct interest in Cody Labs in July 2005. Cody Labs was a privately-owned manufacturer and supplier of bulk active pharmaceutical ingredients. Cody Labs' results of operations will be included in the Company's consolidated financial statements from the date of acquisition, and will be reported in the June 30, 2007 annual report.

The consideration for the April 10, 2007 acquisition was 120,000 contingent shares of Lannett common stock plus the forgiveness of notes receivable and prepayments. In accordance with the agreement, the consideration of 120,000 contingent shares of unregistered Lannett common stock is issuable upon Cody Labs receiving a license from a regulatory agency.

The Company acquired all outstanding stock in this supplier in order to expand the breadth of its product offerings, and to maximize the profit margin on these products being offered.

On March 31, 2007, the Company determined the total \$11.7 million then advanced to this supplier, composed of the \$10.5 million note receivable and the \$1.2 million prepayments, exceeded the value of Cody Labs' net assets by \$7.8 million. Impairment on the notes receivable was recorded effective March 31, 2007, representing the difference between the notes receivable from Cody Labs and the net assets of Cody Labs.

The Company accounted for the transaction by following the guidance under SFAS 15, *Accounting by Debtors and Creditors for Troubled Debt Restructuring* and under the purchase method of accounting as provided in SFAS 141, *Business Combinations*.



**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

**Introduction**

The following information should be read in conjunction with the consolidated financial statements and notes in Part I, Item 1 of this Quarterly Report and with Management's Discussion and Analysis of Financial Condition and Results of Operations contained in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2006.

This Report on Form 10-Q and certain information incorporated herein by reference contain forward-looking statements which are not historical facts made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements which speak only as of the date made. Lannett is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

**Critical Accounting Policies**

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of our financial statements. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We believe that our critical accounting policies include those described below.

**Revenue Recognition** - The Company recognizes revenue when its products are shipped, and when title and risk of loss have transferred to the customer and provisions for estimates, including rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments are reasonably determinable. Accruals for these provisions are presented in the consolidated financial statements as rebates and chargebacks payable and reductions to net sales.

The change in the reserves for various sales adjustments may not be proportional to the change in sales because of changes in both the product mix and the customer mix. Increased sales to wholesalers will generally require additional rebates. Incentives offered to increase sales vary from product to product. Provisions for estimated rebates and promotional and other credits are estimated based on historical experience, estimated

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

customer inventory levels, and contract terms. Provisions for other customer credits, such as price adjustments, returns, and chargebacks require management to make subjective judgments. Unlike branded innovator companies, Lannett does not use information about product levels in distribution channels from third-party sources, such as IMS Health and NDC Health, in estimating future returns and other credits. Lannett calculates a chargeback/rebate rate based on contractual terms with its customers and applies this rate to customer sales. The

major variable affecting this rate is customer mix, and estimates of expected customer mix are based on historical experience and sales expectations. The chargeback/rebate reserve is reviewed on a monthly basis by management using several ratios and metrics. Lannett's methodology for estimating reserves in the three and nine month periods ended March 31, 2007 has been consistent with previous periods.

The Company ships its products to the warehouses of its wholesale and retail chain customers. When the Company and a customer reach an agreement for the supply of a product, the customer will generally continue to purchase the product, stock its warehouse, and resell the product to its own customers. The customer will continually reorder the product as its warehouse is depleted. The Company generally has no minimum size orders for its customers. Additionally, most warehousing customers prefer not to stock excess inventory levels due to the additional carrying costs and inefficiencies created by holding excess inventory. As such, the Company's customers continually reorder the Company's products. It is common for the Company's customers to order the same products on a monthly basis. For generic pharmaceutical manufacturers, it is critical to ensure that customers' warehouses are adequately stocked with its products. This is important due to the fact that several generic competitors compete for the consumer demand for a given product. Availability of inventory ensures that a manufacturer's product is considered. Otherwise, retail prescriptions would be filled with competitors' products. For this reason, the Company periodically offers incentives to its customers to purchase its products. These incentives are generally up-front discounts off its standard prices at the beginning of a generic campaign launch for a newly-approved or newly-introduced product, or when a customer purchases a Lannett product for the first time. Customers generally inform the Company that such purchases represent an estimate of expected resales for a period of time. This period of time is generally up to three months. The Company records this revenue, net of any discounts offered and accepted by its customers at the time of shipment. The shelf-life of the Company's products ranges from 18 months to 36 months from the time of manufacture. The Company monitors its customers' purchasing trends to identify any significant lapses in purchasing activity. If the Company observes a lack of recent activity, inquiries will be made to such customer regarding the success of the customer's resale efforts. The Company attempts to minimize any potential return (or shelf life issues) by maintaining an active dialogue with the wholesale customers.

**Chargebacks** The provision is based upon contracted prices with customers, and the accuracy of this provision is affected by changes in product sales mix and delays in selling products through distributors. This is considered the most significant and complex estimate used in the recognition of revenue. The chargeback is initiated when the Company sells its products to indirect customers such as independent pharmacies, managed care organizations, hospitals, nursing homes, and group purchasing organizations. The Company enters into agreements with its indirect customers to establish pricing for certain products. The indirect customers then select wholesalers from which to purchase the products at these contractual prices.

Upon the sale of a product to a wholesaler, the Company will estimate the chargeback provision required, based upon estimated purchases by indirect customers, each of whom may have varying contracted prices. Once the actual sale to the indirect customer occurs, the wholesaler will request a chargeback credit from the Company. The chargeback is the difference between the contractual price with the indirect customer and the wholesaler's invoice price, if the price sold to the indirect customer is lower than the direct price to the wholesaler. The provision for chargebacks is based on expected sell-through levels by the Company's wholesale customers to the indirect customers. As sales increase to the large wholesale customers, such as Cardinal Health, AmerisourceBergen, and McKesson, the reserve for chargebacks will also generally increase. The size of the chargeback increase depends on the product and customer mix, as different products and customers will have different chargeback rates determined by the contractual sales prices. The Company continually monitors the reserve for chargebacks and makes adjustments as appropriate. Since the chargeback is initiated upon the transfer or sale of the product from the wholesaler to the indirect customer, there is typically a delay in processing the chargeback, based on the time to sell the product. Thus, the estimated chargeback reserve at the time of sale may vary from actual, based on this time delay and the product sales mix going through each distributor. The Company closely monitors this activity to ensure the estimates accurately reflect actual activity.

**Rebates** Rebates are offered to the Company's key customers to promote customer loyalty and encourage greater product sales. These rebate programs provide customers with rebate credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. At the time of shipment, the Company estimates reserves for rebates and other promotional credit programs based on the specific terms in each agreement. The reserve for rebates increases as sales to certain wholesale and retail customers increase. However, these rebate programs are tailored to the customers' individual programs. Hence, the reserve will depend on the mix of customers that comprise such rebate programs.

**Returns** Consistent with industry practice, the Company has a product returns policy that allows certain customers to return product within a specified period prior to and subsequent to the product's lot expiration date in exchange for a credit to be applied to future purchases. The Company's policy requires that the customer obtain approval from the Company for any qualifying return. The Company estimates its provision for returns based on historical experience, changes to business practices, and credit terms. While such experience has allowed for reasonable estimations in the past, history may not always be an accurate indicator of future returns. The Company continually monitors the provisions for returns and makes adjustments when management believes that actual product returns may differ from established reserves. Generally, the reserve for returns increases as net sales increase. The reserve for returns is included in the rebates and chargebacks payable account on the balance sheet.

**Other Adjustments** Other adjustments consist primarily of price adjustments, also known as shelf stock adjustments, which are credits issued to reflect decreases in the selling prices of the Company's products that customers have remaining in their inventories at the time of the price reduction. Decreases in selling prices are discretionary decisions made by management to reflect competitive market conditions. Amounts recorded for estimated shelf stock adjustments are based upon specified terms with direct customers, estimated declines in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments are included in the rebates and chargebacks payable account on the balance sheet.

The following tables identify the reserves for each major category of revenue allowance and a summary of the activity for the nine months ended March 31, 2007 and 2006:

**For the nine months ended March 31, 2007**

Reserve Category	Chargebacks	Rebates	Returns	Other	Total
Reserve balance as of June 30, 2006	\$ 10,137,400	\$ 2,183,100	\$ 416,000	\$ 275,600	\$ 13,012,100
Actual credits issued related to sales recorded in prior fiscal years	(10,170,000)	(1,800,000)	(890,000)	(250,000)	(13,110,000)
Reserves or (reversals) charged during Fiscal 2007 related to sales recorded in prior fiscal years		(300,000)	460,000		160,000
Reserves charged to net sales during fiscal 2007 related to sales recorded in fiscal 2007	24,340,700	8,832,300	986,400	1,033,100	35,192,500
Actual credits issued related to sales recorded in Fiscal 2007	(17,065,500)	(5,122,200)	(954,700)	(265,000)	(23,407,400)
Reserve balance as of March 31, 2007	\$ 7,242,600	\$ 3,793,200	\$ 17,700	\$ 793,700	\$ 11,847,200



**For the nine months ended March 31, 2006**

Reserve Category	Chargebacks	Rebates	Returns	Other	Total
Reserve Balance as of June 30, 2005	\$ 7,999,700	\$ 1,028,800	\$ 1,692,000	\$ 29,500	\$ 10,750,000
Actual credits issued related to sales recorded in prior fiscal years	(7,720,000)	(1,450,900)	(1,264,800)	(27,200)	(10,462,900)
Reserves or (reversals) charged during Fiscal 2006 related to sales recorded in prior fiscal years					
Reserves charged to net sales during fiscal 2006 related to sales recorded in fiscal 2006	21,207,000	4,085,800	297,300	912,700	26,502,800
Actual credits issued related to sales recorded in Fiscal 2006	(8,612,100)	(2,313,400)	(273,400)	(892,800)	(12,091,700)
Reserve Balance as of March 31, 2006	\$ 12,874,600	\$ 1,350,300	\$ 451,100	\$ 22,200	\$ 14,698,200

Credits issued during the quarter that relate to prior year sales are charged against the opening balance. Since reserves are assessed and recorded in aggregate, any potential additional reserves or reversals of reserves have historically offset each other. The table above shows the effects of reversals within the rebate and return categories. It is the Company's intention that all reserves be charged to sales in the period that the sale is recognized, however, due to the nature of this estimate, it is possible that the Company may sometimes need to increase or decrease the reserve based on prior period sales. If that were to occur, management would disclose that information at that time. If the historical data the Company uses and the assumptions management makes to calculate its estimates of future returns, chargebacks, and other credits do not accurately approximate future activity, its net sales, gross profit, net income and earnings per share could change. However, management believes that these estimates are reasonable based upon historical experience and current conditions.

Since the Company monitors and assesses these reserves in aggregate, the rates of reserves will vary, as well as the category under which the credit falls. This variability comes about when the Company is working with indirect customers to compete with the pricing of other generic companies. The Company is currently working on improving computer systems to improve the accuracy of tracking and processing chargebacks and rebates. Improvements to automate calculation of reserves will not only reduce the potential for human error, but also will result in more in-depth analysis and improved customer interaction for resolution of open credits. Greater processing automation has already been implemented within the Company. Further solutions are in progress and anticipate a significant portion of the solution to be completed by June 30, 2007.

The rate of credits issued is monitored by the Company on a quarterly basis. The Company may change the estimate of future reserves based on the amount of credits processed, or the rate of sales made to indirect customers. The decrease of reserves to \$11,847,000 at March 31, 2007 from \$13,012,000 at June 30, 2006 is due to the timing of credits being processed by the customers and by the Company. Approximately 99% of the reserve balance from June 30, 2006 has been processed through March 31, 2007. Communication with wholesale customers has improved throughout Fiscal 2007. The result is that a significant amount of credits had been processed, and have reduced the liability as of March 31, 2007. Management estimates reserves based on sales mix. A comparison to wholesaler inventory reports is performed quarterly, in order to justify the balance of unclaimed chargebacks and rebates. The Company has historically found a direct correlation between the calculation of the reserve based on sales mix, and the wholesaler inventory analysis.

Each category of reserve shown has decreased since June 30, 2006, except for a slight increase in the other reserves. An increased level of chargebacks and rebates processed by customers and improved processing by the Company has led to this change. On a quarter to quarter basis, the chargeback reserves may fluctuate, due to the increasingly competitive generic pharmaceutical market. The increased competition in certain drugs and increase in chargebacks has resulted in decreased prices to Lannett customers. Recent quarters have seen declining net sales prices in

certain products, and increases in others.

**Accounts Receivable** - The Company performs credit evaluations of its customers and adjusts credit limits based upon payment history and the customer's current credit worthiness, as determined by a review of available credit information. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within both the Company's expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past.

The Company also regularly monitors customer Accounts Receivable (AR) balances through a tool known as Days Sales Outstanding (DSO). This calculation for Net DSO begins with the Gross AR less the Rebates and Chargeback reserve. This net amount is then divided by the average daily net sales for the period. The table below shows the results of these calculations for the relevant periods:

	Nine Months ended 3/31/06	Fiscal Year ended 6/30/06	Nine Months ended 3/31/07
Net DSO (in days)	52	68	75
Gross DSO (in days)	76	77	79

The Gross DSO above shows the result of the same calculation without regard to rebates and chargebacks. It is generally higher than the Net DSO calculation. The Company monitors both Net DSO and Gross DSO as an overall check on collections and reasonableness of reserves. In order to be effective indicators, both types of DSO are evaluated on a quarterly basis. The Gross DSO calculation provides management with an understanding of the frequency of customer payments, and the ability to process customer payments and deductions. The Net DSO calculation provides management with an understanding of the relationship of the A/R balance net of the reserve liability compared to net sales after reserves charged during the period.

The Company's offers payment terms to its customers that are consistent within the generic industry at 60 days from the date of the invoice. Gross DSO has remained consistent since the prior year. Management is implementing automation to help speed up the collection of customer accounts, in order to reduce the Gross DSO to an amount that is in line with our payment terms extended to customers. If DSO is significantly greater or less than 60 days, the Company will review customer balances and, take necessary action.

Net DSO through the Fiscal 2007 third quarter, net of rebates and chargebacks, increased as a result of changes in the customer sales mix and product sales mix. A decline in sales to one of the major wholesalers has resulted in a large portion of the decrease in chargebacks and rebate reserves. While the addition of a new retail customer during the year has compensated for the loss of those sales, the new sales have been added without the additional liabilities of chargeback and rebate reserves. The net effect is that the sales and receivables have continued to increase, but the associated reserves needed on the sales have declined. The result of such a change is an increase in DSO.

**Inventories** - The Company values its inventory at the lower of cost (determined by the first-in, first-out method) or market, regularly reviews inventory quantities on hand, and records a provision for excess and obsolete inventory based primarily on estimated forecasts of product demand and production requirements. The Company's estimates of future product demand may prove to be inaccurate, in which case it may have understated or overstated the provision required for excess and obsolete inventory. In the future, if the Company's inventory is determined to be overvalued, the Company would be required to recognize such costs in cost of goods sold at the time of such determination. Likewise, if inventory is determined to be undervalued, the Company may have recognized excess cost of goods sold

in previous periods and would be required to recognize such additional operating income at the time of sale.

**Stock Options** - Statement of Financial Accounting Standards ( SFAS ) No. 123 (revised 2004), Share-Based Payment, (123(R)) was adopted effective July 1, 2005. The Company applied the standard using the modified prospective-transition method with no restatement of prior periods. Prior to July 1, 2005, the Company accounted for those plans under the recognition and measurement provisions of APB 25, and related Interpretations, as permitted by SFAS 123. No stock-based employee compensation cost was recognized in the Statement of Operations for the year ended June 30, 2005, as all options granted had an exercise price equal to the market value of the underlying common stock on the date of the grant.

Since the standard was applied using the modified-prospective-transition-method, prior periods have not been restated. Under this method, the Company is required to record compensation expense for all awards granted after the date of adoption and for the unvested portion of previously granted awards that remain outstanding as of the beginning of the period of adoption. Share-based compensation cost is measured using the Black-Scholes option pricing model. The following table highlights relevant stock-option plan information as of March 31:

	2007	2006
Total share-based compensation expense (restated)	\$ 857,000	\$ 1,072,000
Total compensation cost related to non-vested awards not yet recognized (restated)	\$ 1,429,000	\$ 1,568,000
Weighted average period over which it is to be recognized	1.6 years	1.4 years

**Results of Operations - Three months ended March 31, 2007 compared with three months ended March 31, 2006**

Net sales for the three months ended March 31, 2007 ( Fiscal 2007 ) increased 33% to \$20,303,000 from \$15,737,000 for the three months ended March 31, 2006 ( Fiscal 2006 ). The increase was primarily due to greater demand for generic medication used to treat thyroid deficiency, greater demand for generic antibiotics, and new products that were approved by the FDA in the current or previous year. The Company was able to increase sales of thyroid medication through a new customer acquisition and expanded sales to existing customers. In the prior year, the thyroid medications were declining, due to a delay in the AB rating of Levothyroxine. In the current year, the increase is likely due to Lannett's ability to provide the product quickly and cost effectively to all of our customers. The following table highlights the reasons for the increase, and the percentage each area had on the overall increase of \$4,556,000:

Description	% of increase
Greater demand/volume	62%
New product launches	14%
Marketing agreements	79%
Existing product changes	-55%
Total	100%

The majority of the increases are due to sales of products the Company has obtained through marketing and distribution agreements. These products have lower margin than other products, however the increased volume has compensated for the decline in sales of other manufactured products. The result is higher sales with lower margins. These increases may not be indicative of the full year sales growth. Existing product changes are also primarily driven by volume, with a small amount of decline due to pricing.

Edgar Filing: LANNETT CO INC - Form 10-Q/A

The existing product sales decline can be attributed to several products. Sales of products used in the treatment of epilepsy decreased by approximately \$1.2 million in Fiscal 2007 because new manufacturers have entered the market, affecting sales volume. Drugs used to treat congestive heart failure saw a decline of nearly \$600,000 in sales, due primarily to competition and declining prices. Sales of drugs used in hormone replacement therapy

declined \$400,000 in Fiscal 2007 because of greater competition and pricing pressure added by new competitors in the marketplace. Sales of drugs supporting pain management had declined \$700,000 in the quarter, a result of changing suppliers.

The Company sells its products to customers in various categories. The table below identifies the Company's approximate net sales to each category:

Customer Category	Three Months Ended March 31,	
	2007	2006
Wholesaler/Distributor	\$ 12,100,000	\$ 12,256,000
Retail Chain	6,981,000	1,521,000
Mail-Order Pharmacy	1,129,000	1,589,000
Private Label	93,000	371,000
Total	\$ 20,303,000	\$ 15,737,000

The increase in sales to wholesaler/distributor customers is due mainly to current year improvement over prior year issues associated with Levothyroxine Sodium tablets. Excess product already at customer locations in 2005 resulted in sales declines in the quarter ended March 31, 2006. In the quarter ended March 31, 2007, the excess inventory and returns of this product were no longer an issue, and the product was again being sold on a regular basis. Retail chain sales improved over the prior year because of a new customer agreement entered during the quarter ended March 31, 2007.

Cost of sales (excluding amortization of intangible asset) for the third quarter of Fiscal 2007 increased 50% to \$14,127,000 from \$9,404,000 in Fiscal 2006. The increase is due to the 30% increase in sales which was driven mostly by volume. In addition, new product sales and marketing agreements consisted of products that have higher costs to produce or purchase. Gross profit margins (excluding amortization of intangible asset) for the third quarter of Fiscal 2007 and Fiscal 2006 were 30% and 40%, respectively. While the Company is continuously striving to keep product costs low, there can be no guarantee that profit margins will not fluctuate in future periods. Pricing pressure from competitors and costs of producing or purchasing new drugs may also fluctuate in the future. Changes in the future sales product mix may also occur. As can be seen in the mix of increased sales, the greatest increases are of products that are distributed, and not manufactured. These costs have caused the margin percentage to decrease. These changes may affect the gross profit percentage in future periods.

Research and development ( R&D ) expenses in the third quarter increased 81% to \$2,269,000 for Fiscal 2007 from \$1,252,000 for Fiscal 2006. The increase is primarily due to increased activity during the quarter to produce submission batches to the FDA. Drug Bioequivalence studies have increased in preparation for submitting ANDAs to the FDA. The Company expenses all production costs as R&D, including submission batches and Bioequivalence studies, until the drug is approved by the FDA. R&D expenses may fluctuate from period to period, based on R&D plans for submission to the FDA.

Selling, general and administrative expenses in the third quarter increased 23% to \$3,132,000 in Fiscal 2007 from \$2,555,000 in Fiscal 2006. The significant portion of the increase is due to \$.6 million of expenses incurred in Fiscal 2007 that relate to marketing agreements tied to sales of new generic products. Other increases in personnel and legal costs have been offset by reductions in other professional fees. Other costs will continue to be incurred to facilitate improvements in the Company's infrastructure. These costs are expected to be temporary investments in the future of the Company and may not continue at the same level. However, as the Company continues to invest in technology, the Company may need to invest additional funds in technology or professional services.



Amortization expense for the intangible asset for the three months ended March 31, 2007 and 2006 was approximately \$446,000 for each period. The amortization expense relates to the March 23, 2004 exclusive marketing and distribution rights agreement with JSP. For the remaining seven years of the contract, the Company will incur annual amortization expense of approximately \$1,785,000.

The Company determined, during the three months ended March 31, 2007, that the Cody Labs receivables were impaired by approximately \$7,776,000. An independent valuation was obtained as of April 10, 2007. After that valuation was received, management concluded that the net assets of Cody Labs as of March 31, 2007 were less than the note receivable and prepayments outstanding as of March 31, 2007. The impairment of \$7,775,890 is the difference between the amount outstanding from Cody Labs of March 31, 2007 and the value of net assets of Cody Labs.

The Company's interest expense in the third quarter increased to \$76,000 in Fiscal 2007 from \$65,000 in Fiscal 2006 as a result of an increase interest rates over the prior year. Interest income in the third quarter increased marginally to \$99,000 in Fiscal 2007 from \$96,000 in Fiscal 2006.

The Company had an income tax benefit in the third quarter that amounted to \$819,000 in Fiscal 2007 compared to an income tax expense of \$856,000 in Fiscal 2006, with an 11% and 41% effective tax rate, respectively.

The Company reported a net loss of \$6,607,000 in the third quarter of Fiscal 2007, or \$0.27 basic and diluted loss per share, as compared to net income of \$1,255,000 in the third quarter of Fiscal 2006, or \$0.05 basic and diluted income per share.

**Results of Operations - Nine months ended March 31, 2007 compared with nine months ended March 31, 2006**

Net sales for the nine months ended March 31, 2007 ( Fiscal 2007 ) increased 46% to \$65,187,000 from \$44,607,000 for the nine months ended March 31, 2006 ( Fiscal 2006 ). The increase was primarily due to greater demand for generic medication used to treat thyroid deficiency, greater demand for generic antibiotics, and new products that were approved by the FDA in the current or previous year. The Company was able to increase sales of thyroid medication through a new customer agreement in the first quarter of Fiscal 2007 and to existing customers. In the prior year, the thyroid medications were declining, due to a delay in the AB rating of Levothyroxine. In the current year, the increase is due to Lannett's ability to provide the product quickly and cost effectively to all of our customers. The following table highlights the reasons for the increase, and the percentage each area had on the overall increase of \$20,579,000:

Description	% of increase
Greater demand/volume	69%
New product launches	9%
Marketing agreements	64%
Existing product changes	-42%
Total	100%

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

The majority of the increases are due to increased volumes. However, these increases may not be indicative of the full year sales growth. Existing product changes are also primarily driven by volume, with a small amount of decline due to pricing.

The existing product sales decline can be attributed to several products. Sales of products used in the treatment of epilepsy decreased by approximately \$3.4 million in Fiscal 2007 because new manufacturers have entered the market, affecting sales volume. Sales of migraine headache pharmaceuticals declined \$800,000. This decline can be attributed to a combination of lower product sales prices, and increased competition. Sales of drugs used in hormone replacement therapy declined \$1.3 million in Fiscal 2007 because of greater competition and pricing pressure added by new competitors in the marketplace.

The Company sells its products to customers in various categories. The table below identifies the Company's approximate net sales to each category:

Customer Category	Nine Months Ended March 31,	
	2007	2006
Wholesaler/Distributor	\$ 40,692,000	\$ 30,495,000
Retail Chain	20,167,000	6,979,000
Mail-Order Pharmacy	4,138,000	5,094,000
Private Label	190,000	2,039,000
Total	\$ 65,187,000	\$ 44,607,000

The increase in sales to wholesaler/distributor customers is due mainly to improvement in sales of generic medication used in the treatment of thyroid deficiency. The prior year sales were affected by lower-than-expected demand and lower sales to wholesalers. In the nine months ended March 31, 2006, the excess inventory and returns of this product were no longer an issue, and the product was again being sold on a regular basis. In addition, a newly marketed product has been offered in Fiscal 2007 which has increased sales through all channels. Retail Chain sales of the thyroid medication also increased, a result of a new customer agreement entered during the current fiscal year.

Cost of sales (excluding amortization of intangible asset) for the first nine months increased 84% to \$44,770,000 in Fiscal 2007 from \$24,331,000 in Fiscal 2006. The increase is due to the 46% increase in sales which was driven mostly by volume. In addition, new product sales obtained through marketing agreements have a higher cost of sales percentage, 55% on average, replacing declining manufactured product sales which historically had a much lower cost of sales percentage, and higher profit margins. Gross profit margins (excluding amortization of intangible asset) for the first nine months of Fiscal 2007 and Fiscal 2006 were 31% and 45%, respectively. While the Company is continuously striving to keep product costs low, there can be no guarantee that profit margins will not fluctuate in future periods. Pricing pressure from competitors and costs of producing or purchasing new drugs may also fluctuate in the future. Changes in the future sales product mix may also occur. These changes may affect the gross profit percentage in future periods.

Research and development ( R&D ) expenses in the first nine months increased 16% to \$5,586,000 for Fiscal 2007 from \$4,814,000 for Fiscal 2006. The increase is primarily due to increased activity during the most recent quarter to produce submission batches to the FDA. Drug Bioequivalence studies have increased in preparation for submitting ANDAs to the FDA. The Company expenses all production costs as R&D, including submission batches and Bioequivalence studies, until the drug is approved by the FDA. R&D expenses may fluctuate from period to period, based on R&D plans for submission to the FDA.

Selling, general and administrative expenses in the first nine months increased 29% to \$9,486,000 in Fiscal 2007 from \$7,332,000 in Fiscal 2006. The significant portion of the increase is due to \$1.8 million of expenses incurred in Fiscal 2007 that relate to marketing agreements tied to sales of new generic products. The remaining increase in expense is due to additional administrative personnel costs, related to increased headcount, professional fees and computer support fees. While the Company is focused on controlling costs, increases in personnel costs may have an ongoing and longer lasting impact on the administrative cost structure. Other costs are being incurred to facilitate improvements in the Company's infrastructure. These costs are expected to be temporary investments in the future of the Company and may not continue at the same level. However, as the Company continues to invest in technology, the Company may need to invest additional funds in technology or professional services.

Amortization expense for the intangible asset for the nine months ended March 31, 2007 and 2006 was approximately \$1,338,000 for each period. The amortization expense relates to the March 23, 2004 exclusive marketing and distribution rights agreement with JSP.



The Company determined, during the nine months ended March 31, 2007, that the Cody Labs receivables were impaired by approximately \$7,776,000. An independent valuation was obtained as of April 10, 2007. After that valuation was received, management concluded that the net assets of Cody Labs as of March 31, 2007 were less than the note receivable and prepayments outstanding as of March 31, 2007. The impairment of \$7,775,890 is the difference as of March 31, 2007 between the amount outstanding from Cody Labs and the value of net assets of Cody Labs.

The Company's interest expense in the first nine months decreased to \$208,000 in Fiscal 2007 from \$250,000 in Fiscal 2006 primarily as a result of a decrease in principal balances. Interest income in the first nine months decreased to \$310,000 in Fiscal 2007 from \$334,000 in Fiscal 2006.

The Company's income tax expense in the first nine months decreased to \$686,000 in Fiscal 2007 from \$2,752,000 in Fiscal 2006, with a 40% effective tax rate in Fiscal 2006. Timing differences relating to tax treatment of the impairment has led the Company to record income tax expense even though the Company has recorded a net loss before taxes.

The Company reported net loss of \$4,354,000 in the first nine months of Fiscal 2007, or \$0.18 basic and diluted loss per share, as compared to net income of \$4,123,000 in the first nine months Fiscal 2006, or \$0.17 basic and diluted income per share.

#### Liquidity and Capital Resources

**The Company has historically financed its operations by cash flow from operations. At March 31, 2007, working capital was \$23,943,000, as compared to \$23,446,000 at June 30, 2006, an increase of \$497,000. Net cash provided by operating activities of \$11,535,000 in the first nine months of Fiscal 2007 is due to net loss of \$4,354,000, and adjustments for the effects of non-cash items of \$12,622,000 and increase in operating assets and liabilities of \$3,268,000. Significant changes in operating assets and liabilities are comprised of:**

Trade accounts receivable net of rebates and chargebacks payable increased \$5,188,000 due to an increase in sales;

A \$935,000 increase in inventories resulting from increased demand for distributed products;

A \$8,639,000 increase in accounts payable due to timing of payments at the end of the month combined with increased spending on products for resale, primarily Levothyroxine Sodium tablets; and

A \$366,000 decrease in prepaid taxes relating to estimated federal tax payments made during the Fiscal year.

The Company monitors both Net DSO and Gross DSO as an overall check on collections and reasonableness of reserves. In order to be effective indicators, both types of DSO are evaluated on a quarterly basis. The Gross DSO calculation provides management with an understanding of the frequency of customer payments, and the ability to process customer payments and deductions. The Net DSO calculation provides management with an understanding of the relationship of the A/R balance net of the reserve liability compared to net sales after reserves charged during the period. Standard payment terms offered to customers are consistent with industry practice at 60 days.

For the nine months of Fiscal 2007, this Gross DSO amounted to 79 days. This item has remained consistent throughout the Fiscal year, and is a result of the timing required to process customer credits, which often have a delay coming from the wholesale customers. Some delays were the result of customers failing to report all credits, while some were the responsibility of the Company to act upon. As of the date of this filing, all customer processing issues have been reconciled, and the Company anticipates that Gross DSO will be in the 60 to 70 day range in future reports, as the payment terms for most customers are 60 days.

The Net DSO Calculation provides us with an understanding of the relationship of the A/R balance net of the reserve liability compared to net sales after reserves charged during the period. It eliminates the effect of timing of processing, which is inherent in the Gross DSO calculation. A Net calculation greater than 60 days may indicate under-reserved sales, while an amount less than 60 days may indicate over-reserved sales or changes in the customer mix. This figure is expected to approximate 60 days, the normal credit terms. For the nine months of Fiscal 2006, this Net DSO amounted to 75 days. The increase is due to changes in the customer sales mix, with increasing sales being made to customers with no reserve requirements.

The net cash used in investing activities of \$7,390,000 for the nine months ended March 31, 2007 was due to an additional \$7,327,000 note receivable and \$1,949,000 investment in facilities and equipment. This was partially

offset by the sale of \$1,877,000 of the Company's investment securities, which consist primarily of U. S. government and agency marketable debt securities.

The following table summarizes the remaining repayments of debt, including sinking fund requirements as of March 31, 2007 for the subsequent twelve month periods:

Twelve Month Periods	Amounts Payable to Institutions
2007	\$ 597,000
2008	607,000
2009	462,000
2010	4,810,000
2011	214,000
Thereafter	1,100,000
	\$ 7,790,000

The Company has a \$3,000,000 line of credit from Wachovia Bank, N.A. that bears interest at the prime interest rate less 0.25% (8.0% at March 31, 2007). The line of credit was renewed and extended to November 30, 2007. At March 31, 2007 and 2006, the Company had \$0 outstanding under the line of credit. The line of credit is collateralized by substantially all of the Company's assets. The Company currently has no plans to borrow under this line of credit.

The terms of the line of credit, the loan agreement, the related letter of credit and the 2003 Loan Financing require that the Company meet certain financial covenants and reporting standards, including the attainment of standard financial liquidity and net worth ratios. As of March 31, 2007, the Company has complied with such terms, and successfully met its financial covenants.

In July 2004, the Company received \$500,000 of grant funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development. The grant funding program requires the Company to use the funds for machinery and equipment located at their Pennsylvania locations, hire an additional 100 full-time employees by June 30, 2006, operate its Pennsylvania locations a minimum of five years and meet certain matching investment requirements. If the Company fails to comply with any of the requirements above, the Company would be liable to the full amount of the grant funding (\$500,000). The Company records the unearned grant funds as a liability until the Company complies with all of the requirements of the grant funding program. On a quarterly basis, the Company will monitor its progress in fulfilling the requirements of the grant funding program and will determine the status of the liability. As of March 31, 2007, the Company has recognized the grant funding as a current liability under the caption of Unearned Grant Funds, because the Company has met approximately 50% of the requirement to add 100 full-time employees. However, the Company is requesting an extension of this obligation to add 100 employees, since the other requirement related to use of funds has been met already, and the time requirement to operate its Pennsylvania locations is still ongoing.

Except as set forth in this report, the Company is not aware of any trends, events or uncertainties that have or are reasonably likely to have a material adverse impact on the Company's short-term or long-term liquidity or financial condition.

#### Prospects for the Future

## Edgar Filing: LANNETT CO INC - Form 10-Q/A

The Company has several generic products under development. These products are all orally-administered topical and parenteral products designed to be generic equivalents to brand named innovator drugs. The Company's developmental drug products are intended to treat a diverse range of indications. As the oldest generic drug manufacturer in the country, formed in 1942, Lannett currently owns several ANDAs for products

which it does not manufacture and market. These ANDAs are simply dormant on the Company's records. Occasionally, the Company reviews such ANDAs to determine if the market potential for any of these older drugs has recently changed, so as to make it attractive for Lannett to reconsider manufacturing and selling it. If the Company makes the determination to introduce one of these products into the consumer marketplace, it must review the ANDA and related documentation to ensure that the approved product specifications, formulation and other factors meet current FDA requirements for the marketing of that drug. The Company would then redevelop the product and submit it to the FDA for supplemental approval. The FDA's approval process for ANDA supplements is similar to that of a new ANDA. Generally, in these situations, the Company must file a supplement to the FDA for the applicable ANDA, informing the FDA of any significant changes in the manufacturing process, the formulation, or the raw material supplier of the previously-approved ANDA.

A majority of the products in development represent either previously approved ANDAs that the Company is planning to reintroduce (ANDA supplements), or new formulations (new ANDAs). The products under development are at various stages in the development cycle—formulation, scale-up, and/or clinical testing. Depending on the complexity of the active ingredient's chemical characteristics, the cost of the raw material, the FDA-mandated requirement of bioequivalence studies, the cost of such studies and other developmental factors, the cost to develop a new generic product varies. It can range from \$100,000 to \$1 million. Some of Lannett's developmental products will require bioequivalence studies, while others will not—depending on the FDA's Orange Book classification. Since the Company has no control over the FDA review process, management is unable to anticipate whether or when it will be able to begin producing and shipping additional products.

In addition to the efforts of its internal product development group, Lannett has contracted with several outside firms for the formulation and development of several new generic drug products. These outsourced R&D products are at various stages in the development cycle—formulation, analytical method development and testing and manufacturing scale-up. These products are orally-administered solid dosage, injectables, as well as topical products intended to treat a diverse range of medical indications. It is the Company's intention to ultimately transfer the formulation technology and manufacturing process for all of these R&D products to the Company's own commercial manufacturing sites. The Company initiated these outsourced R&D efforts to complement the progress of its own internal R&D efforts.

Lannett also manufactures and sells products which are equivalent to innovator drugs which are grand-fathered, under FDA rules, prior to the passage of the Hatch-Waxman Act of 1984. The FDA allows generic manufacturers to produce and sell generic versions of such grand-fathered products by simply performing and internally documenting the product's stability over a period of time. Under this scenario, a generic company can forego the time required for FDA ANDA approval.

The Company signed supply and development agreements with Olive Healthcare, of India; Orion Pharma, of Finland; Azad Pharma AG, of Switzerland, and is in negotiations with companies in Israel for similar new product initiatives, in which Lannett will market and distribute products manufactured by third parties. Lannett intends to use its strong customer relationships to build its market share for such products, and increase future revenues and income.

The majority of the Company's R&D projects are being developed in-house under Lannett's direct supervision and with Company personnel. Hence, the Company does not believe that its outside contracts for product development and manufacturing supply are material in nature, nor is the Company substantially dependent on the services rendered by such outside firms. Since the Company has no control over the FDA review process, management is unable to anticipate whether or when it will be able to begin producing and shipping such additional products.

Lannett may increase its focus on certain specialty markets in the generic pharmaceutical industry. Such a focus is intended to provide Lannett customers with increased product alternatives in categories with relatively few market participants. While there is no guarantee that Lannett has the market expertise or financial resources



necessary to succeed in such a market specialty, management is confident that such future focus will be well received by Lannett customers and increase shareholder value in the long run.

The Company plans to enhance relationships with strategic business partners, including providers of product development research, raw materials, active pharmaceutical ingredients as well as finished goods. Management believes that mutually beneficial strategic relationships in such areas, including potential financing arrangements, partnerships, joint ventures or acquisitions, could allow for potential competitive advantages in the generic pharmaceutical market. For example, the Company has entered into prepayment arrangements in exchange for discounted purchase prices on certain active pharmaceutical ingredients (API) and oral dosage forms. The Company has also arranged for a loan to a certain API provider as well as continued funding of recent operations of this API provider that should facilitate the availability of difficult to source material in the future. The Company plans to continue to explore such areas for potential opportunities to enhance shareholder value.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The Company has debt instruments with variable interest rates. The Equipment loan, amounting to \$802,000 at March 31, 2007, bears interest at a variable rate equal to the LIBOR rate plus 150 basis points. The revenue bonds issued by the Philadelphia Authority for Industrial Development, amounting to \$905,000 at March 31, 2007, bear interest at a floating rate which is equal to the minimum rate of interest necessary to sell the bonds at a price equal to the principal balance. In addition, the Company has a \$3 million line of credit that bears interest at the prime interest rate less 0.25%. The Company currently has \$0 outstanding under this line of credit. Loans are collateralized by inventory, accounts receivable and other assets. The agreement contains covenants with respect to working capital, net worth and certain ratios, as well as other covenants.

The Company invests in U.S. treasury notes, government asset-backed securities and mortgage-backed securities, all of which are exposed to interest rate fluctuations. The interest earned on these investments may vary based on fluctuations in the interest rate.

**ITEM 4. CONTROLS AND PROCEDURES**

*Disclosure Controls and Procedures*

We carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the Exchange Act), as amended for financial reporting as of March 31, 2007. As a result of the restatement described in the Explanatory Note and Note 2 to the consolidated financial statements, management has since concluded that, as of March 31, 2007, these controls and procedures were not effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported as specified in Securities and Exchange Commission rules and forms. As a result of the restatement described in the Explanatory Note and Note 2 to the consolidated financial statements, management has since concluded that the Company did not maintain effective controls over reconciling work-in-process inventory and accounting for non-routine transactions. These control deficiencies resulted in the restatement of the Company's consolidated financial statements as of and for the three months and nine months ended March 31, 2007. At the end of the period management has assessed the controls to not be effective.

**Internal Control Over Financial Reporting Weaknesses**

Management identified a material weakness with respect to the failure to correctly process inventory and cost of goods sold amounts in the company's information system in addition to failure to detect such processing error through account reconciliations. Absent control improvements including improved inventory counting procedures and improved account reconciliation procedures, a material misstatement could occur in the annual financial statements as they did occur in the interim financial statements. While we have identified and implemented additional control improvements, such controls were not operating effectively at March 31, 2007.



We have engaged in, and continue to engage in, substantial efforts to address the material weakness in our internal control over financial reporting and the ineffectiveness of our disclosure controls and procedures.

The Company has remediated its material weakness through the following actions:

Including WIP in cycle counting and quarterly count procedures. The proper execution of inventory cycle counts and period-end inventory counts will add a level of assurance that the balance is correctly stated.

Reconciliation of systems transactions to be performed and reviewed on a monthly basis to ensure that WIP value in inventory systems agrees to WIP value in general ledger accounts.

Revision of monthly closing checklist to include each trial balance account, and identify a specific person responsible for reconciling and reviewing each account as appropriate.

Analysis of detailed WIP inventory, and review of such analysis, to ensure the balance is reasonable in comparison to actual production activities.

Engage SAP consulting experts to review processes that are used to close WIP batches.

Management identified a material weakness with respect to the recording an impairment of the loans to Cody Labs during the proper interim reporting period. Absent control improvements including document review and financial evaluation of all contracts and agreements, a material misstatement could occur in the annual financial statements as they did occur in the interim financial statements. While we have identified and implemented additional control improvements, such controls were not operating effectively at March 31, 2007.

We have engaged in, and continue to engage in, substantial efforts to address the material weakness in our internal control over financial reporting and the ineffectiveness of our disclosure controls and procedures.

The Company has remediated its material weakness through the following actions:

Formalize and enforce company policy to require either CEO or CFO signature on all material company contracts.

Formalize and enforce company policy to require legal review of all material Lannett contracts prior to execution.

Formalize and enforce company policy to require all material Lannett contracts are provided to Lannett's Corporate Controller and CFO in a timely manner to allow for appropriate accounting review and analysis.

Request that Lannett's outside attorney provide management with a quarterly report identifying all Lannett contracts reviewed during that quarter.

Lannett's Disclosure Committee will review the outside attorney provided quarterly report to determine materiality and appropriate disclosure.

**Changes in Internal Control Over Financial Reporting**

There were no significant changes in the Company's internal controls or, to the knowledge of management of the Company, in other factors that could significantly affect internal controls subsequent to the date of the Company's most recent evaluation of its disclosure controls and procedures utilized to compile information included in this filing.

**PART II. OTHER INFORMATION**

***ITEM 1. LEGAL PROCEEDINGS***

**Regulatory Proceedings**

The Company is engaged in an industry which is subject to considerable government regulation relating to the development, manufacturing and marketing of pharmaceutical products. Accordingly, incidental to its business, the Company periodically responds to inquiries or engages in administrative and judicial proceedings involving regulatory authorities, particularly the FDA and the Drug Enforcement Agency.

**DES Cases**

The Company is currently engaged in several civil actions as a co-defendant with many other manufacturers of Diethylstilbestrol ( DES ), a synthetic hormone. Prior litigation established that the Company's pro rata share of any liability is less than one-tenth of one percent. The Company was represented in many of these actions by the insurance company with which the Company maintained coverage during the time period that damages were alleged to have occurred. The insurance company denies coverage for actions alleging involvement of the Company filed after January 1, 1992. With respect to these actions, the Company paid nominal damages or stipulated to its pro rata share of any liability. The Company has either settled or is currently defending over 500 such claims. At this time, management is unable to estimate a range of loss, if any, related to these actions. Management believes that the outcome of these cases will not have a material adverse impact on the financial position or results of operations of the Company.

***ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K***

(a) A list of the exhibits required by Item 601 of Regulation S-K to be filed as a part of this Form 10-Q is shown on the Exhibit Index filed herewith.

**SIGNATURE**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**LANNETT COMPANY, INC.**

Dated: October 9, 2007

By: /s/ Brian Kearns  
Brian Kearns  
Vice President of Finance, Treasurer and  
Chief Financial Officer

Dated: October 9, 2007

By: /s/ Arthur P. Bedrosian  
Arthur P. Bedrosian  
President and Chief Executive Officer

**Exhibit Index**

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Herewith
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Herewith
32	Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Herewith